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Breast cancer is one of the leading causes of death in women. Even with advances in early-
stage breast cancer treatment, physicians are still lacking the ability to precisely predict which 
patients would benefit from adjuvant chemotherapy. Gene expression profiling studies have 
been used to provide us with insights into the heterogeneity of breast cancer. Therefore, 
patterns of gene activity can be identified by genome-wide measures of gene expression to 
subclassify tumours. This might provide a better means, than is currently available, of treating 
patients with breast cancer, and to help physicians find the accurate treatment (Wang, Klijn et 
al. 2005). This study uses a combination of three different clustering methods: Hierarchical 
clustering, Self-organizing maps (SOM) and Ward method to further explore and validate the 
characters of previously identified, novel, 306 intrinsic genes thought to discriminate five 
types of breast cancer (LumA, LumB, Normal-like, Basal-like and Her2). It is also used to 
derive improved cluster characterisations for accurate subtype identification from independent 
gene expression data analyses. Implementation of these methods, in widespread clinical 
practice at present, remains limited. From an exploratory pilot study in this research, it was 
found that one or more of the few most highly active genes in one subtype can be active in 
one or more other subtypes indicating that several gene markers are essential for subtype 
discrimination. Nevertheless, this study identified one or two potential genes for some 
IV 
 
subtypes that may be useful as markers in their identification.  In the main part of the 
investigation, the originally selected whole gene set was assessed for their efficacy in subtype 
discrimination using Hierarchical clustering and SOM, both in conjunction with Ward method 
that indicates the optimum number of clusters (subtypes).  Hierarchical-Ward method found 6 
clusters and SOM-Ward method found 7 clusters as optimum compared to the 5 subtypes 
reported by the original authors from whose work the gene set used in this study was 
extracted.  This indicated the heterogeneity of subtypes.  In both methods, second optimum 
number of clusters was 2.  Our clusters revealed interesting results:  for example, closer 
examination of the 2 cluster structure from both Herarchical-Ward and SOM-Ward indicated 
that 3 subtypes (LumA, LumB and Normal-like) always cluster together and the other 2 
subtypes (Basal and Her2) make up the second cluster.   
The six and 7 optimum clusters from the two respective methods did indicate that most 
clusters contain patients from more than one subtype and revealed which subtypes are more 
likely to cluster together. These results indicate subtype overlap. Although not featured highly 
in SOM-Ward results, the 6 cluster format from this method was explored to compare with 
Herarchical-Ward results and outcomes from the two methods were identical.  This gives 
validity to the results in the study. Interestingly, two out of the 7 clusters from SOM consisted 
of only one subtype each (LumA or Basal-like), and 1 out 6 clusters from Heirarchical-Ward 
also contained only one subtype (LumA); but these clusters did not contain all of the patients 
originally thought to be belonging to each particular subtype.  However, these clusters 
containing only one subtype each may indicate the core behaviour of the respective subtype 
and is worth exploring further. The results overall points to the complexity of discriminating 
the subtypes due to their heterogeneity and overlap, when viewed through the selected set of 
306 intrinsic genes; this study has shed light on these characteristics in a reliable and 
predictable way.   
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Chapter One 
 
1 BACKGROUND 
 
Breast cancer is a disease in which some cells multiply without control to form an abnormal 
mass. The most common form of breast cancer originates in the cells that line the ducts that 
carry milk to the nipple (ductal carcinoma). Other forms of breast cancer originate from the 
glands that produce milk (lobular cancer) or from other parts of the breast. Breast cancer is a 
common cause of death in women in New Zealand and worldwide (Ref. Global Cancer 
Statistics). Although Breast cancer occurs in both men and women, statistics show that this 
disease occurs 100 times more frequently in women than in men (Sasco, Lowenfels et al. 
1993).  
Globally, breast cancer incidence rates are highest in North America and northern Europe 
although incidence rate is decreasing in these parts of the world. The incidence rate is usually 
considered the lowest in Asia and Africa but there has been an increase in the rate in the 
recent years. These international differences are thought to be related to societal changes 
occurring during industrialization (e.g. changes in fat intake, body weight, age at menarche, 
and/or lactation, and reproductive patterns such as fewer pregnancies and later age at first 
birth) (Parkin, Bray et al. 2005). Studies of increasing breast cancer among first-generation 
daughters of Japanese Americans suggest that environmental and lifestyle factors are of 
greater significance than are genetic factors in explaining international differences in breast 
cancer risk (Johnson 2001; Deapen, Liu et al. 2002; Lacey, Devesa et al. 2002). Since 1975, 
mortality rates of Breast cancer have declined. These were because of the improvements of 
adjuvant therapies and attributed to the increased use of screening mammography (Berry, 
Cronin et al. 2005). 
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1.1 Aetiology and risk factors 
 
The frequency of this disease in women has prompted an intensive study of risk factors for 
developing breast cancer to gain clues as to its aetiology as well as to identify modifiable risk 
factors that would be helpful for prevention strategies. Risk factors of breast cancer include 
age and gender. These are considered as one of the strongest risk factors (Jemal, Siegel et al. 
2010). It is rarely found before the age of 25 except in some certain familial cases. The 
incidence rises throughout women’s lifetime (Robbins and cotrans), Race and ethnicity is 
another factor. In the US, although breast cancer is common in women of every major ethnic 
group there are interracial differences (Pike, Spicer et al. 1993; Peto and Mack 2000; Bradley, 
Given et al. 2002; Palmer, Wise et al. 2003; Jatoi, Chen et al. 2007; Jemal, Thun et al. 2008; 
Society 2009 - 2010). Much of these ethnic differences are attributable to factors associated 
with lifestyle and socioeconomic status (e.g. access to diagnosis and treatment).  
Several lifestyle factors including body size, physical activity and dietary factors can 
contribute to the risk of breast cancer (van den Brandt, Spiegelman et al. 2000; Morimoto, 
White et al. 2002; Feigelson, Jonas et al. 2004; Lahmann, Hoffmann et al. 2004; Eliassen, 
Colditz et al. 2006; Ahn, Schatzkin et al. 2007).  
Reproductive and hormonal factors such as prolonged exposure to higher concentrations of 
endogenous estrogen increases the risk of breast cancer (Kelsey, Gammon et al. 1993; Parkin, 
Bray et al. 2005).  
Family history is an important risk factor for breast cancer where strong genetic mutations 
with little relation to environmental differences have been reported (Lichtenstein, Holm et al. 
2000; Peto and Mack 2000; Ahn, Schatzkin et al. 2007). 
Exposure to ionizing radiation of the chest at a young age, as occurs with radiotherapy 
treatment or in survivors of atomic bomb or nuclear plant accidents, is associated with an 
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increased risk of breast cancer (Guibout, Adjadj et al. 2005; Pukkala, Kesminiene et al. 2006; 
Ostroumova, Preston et al. 2008). 
 
1.2 Pathology 
 
More than 95 percent of breast malignancies arise from the breast epithelial elements and are 
therefore carcinomas. The term "breast carcinoma" encompasses a diverse group of lesions 
that differ in microscopic appearance and biologic behaviour, although these disorders are 
often discussed as a single disease.   
The invasive breast carcinomas consist of several histological subtypes. These include 
infiltrating ductal (76 %), invasive lobular (8 %), ductal/lobular (7%), mucinous (colloid) 
(2.4%), tubular (1.5%), medullary (1.2%), and papillary (1%). 
 
1.3 Symptoms and Signs  
 
Most women with symptomatic rather than screen-detected breast cancer present with a 
painless increasing mass which may also be associated with nipple discharge, skin tethering, 
ulceration and, in inflammatory cancers, oedema and erythema. In developing countries, 80% 
are likely to be present with advanced disease and metastases. (Clark 2009) 
Breast cancer can also present as a subtle change in the general appearance of the breast, such 
as an increase or decrease in size, a change in symmetry. There are conditions that may 
resemble the symptoms of breast cancer such as those related to menstrual cycles (cyclic or 
non-cyclic), and whether these symptoms are aggravated or alleviated by any activities or 
medications (Blake Cady 1998; Monica Morrow 2000). 
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1.4 Diagnostic investigations 
 
The diagnostic evaluation of a patient suspected of having breast cancer includes screening 
and diagnostic breast imaging and breast biopsy. The majority of breast cancers are diagnosed 
as a result of an abnormal mammogram, but not all mammographic findings represent cancer 
(Stomper 2000; Ostroumova, Preston et al. 2008). It has been reported that fewer than 10 
percent of cancers can be detected solely by physical examination and over 90 percent 
mammographically (Ostroumova, Preston et al. 2008). Positive mammographic findings 
mainly represent soft tissue masses and microcalcifications.  
 
Contrast-enhanced breast magnetic resonance imaging (MRI) may complement 
mammographic staging, because the latter is more sensitive and is assumed that it would 
estimate the extent of disease more accurately than conventional imaging. However, the MRI 
may sometimes produce falsely positive result and can delay treatment by necessitating 
additional biopsies (Berg, Gutierrez et al. 2004; Bleicher, Ciocca et al. 2009). 
 
Targeted ultrasonography is a useful diagnostic test to evaluate a palpable mass or an area of 
abnormality detected on mammogram. It is particularly useful for assessing whether a mass is 
solid or cystic in nature.  
 
Chest radiography, abdominal/pelvic computed tomography (CT) scanning, and bone scans 
are other techniques commonly used in evaluating different body parts for the presence of 
metastatic disease.  
 
Abnormal screening mammogram often needs further diagnostic evaluation with 
magnification views, spot compression views, targeted ultrasonography, tissue sampling or 
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biopsy (Barlow, Lehman et al. 2002). Biopsy helps obtaining sufficient diagnostic material 
using the least invasive approach and to avoid surgical excision of benign lesions (Barlow, 
Lehman et al. 2002). 
 
Fine needle aspiration (FNA) is a classical method to determine the histopathological features 
of breast lumps by obtaining samples from cellular lesions and metastatic lymph nodes. A 
major advantage of FNA is that it can be easily and quickly performed at the time of a 
diagnostic study, with potential for an immediate preliminary interpretation (Pisano, Fajardo 
et al. 2001). However, the FNA has some disadvantages and produce false negative results in 
inexperienced hands (Pisano, Fajardo et al. 2001). 
 
Core needle biopsy (CNB) is a procedure that removes small but solid samples of tissue using 
a hollow "core" needle that has a special cutting edge. Compared to FNA, CNB offers a more 
definitive histological diagnosis, avoids inadequate samples and may permit the distinction 
between invasive versus in situ cancer (Verkooijen 2002).  
 
Tumour markers are used to assess the estrogen receptor (ER), progesterone receptor (PR), 
and human epidermal growth factor receptor 2 (HER2) status, and should be made on every 
primary invasive breast cancer to identify patients likely to benefit from endocrine and/or 
anti-HER2 therapy (Verkooijen 2002). 
 
1.5 Treatment  
1.5.1 Early breast cancer 
 
The treatment of early breast cancer includes the treatment of locoregional disease with 
surgery, radiation therapy, or both, and the treatment of systemic disease with one or a 
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combination of chemotherapy, endocrine therapy, or biologic therapy. The need for, timing, 
and selection of therapy are based upon tumour variables such as histology, stage, and tumour 
markers; patient variables such as age, menopausal status, and comorbid conditions; as well as 
patient preference, such as a desire for breast preservation (Clark 2009).  
 
1.5.2 Neoadjuvant systemic therapy 
 
Neoadjuvant systemic therapy prior to local treatment may be required to improve surgical 
outcomes and options. For operable breast cancer, the aim is to increase the chance of breast 
conserving surgery in patients who would otherwise require mastectomy. For inoperable 
locally advanced breast cancers, the aim is to achieve operability. 
 
Surgery as a local treatment may vary from wide local excision or segmental mastectomy and 
breast conservation for masses < 4 cm in diameter, to simple mastectomy with or without 
reconstruction. The choice is dictated by the location and extent of the breast mass in relation 
to the breast size, and patient preferences (Clark 2009). Breast cancer surgery has changed 
dramatically over the past several decades and continues to evolve (Cuzick, Stewart et al. 
1994). 
 
Radiotherapy is another local treatment that is given to the conserved breast after wide local 
excision to reduce local recurrence and to the chest wall after mastectomy if there are risk 
factors such as proximity to surgical margins or lymph node metastases, to complete the local 
control measures. 
 
Adjuvant systemic therapy is also a local treatment that refers to the administration of 
endocrine therapy, chemotherapy, and/or biologic therapy after definitive local therapy for 
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breast cancer. Adjuvant systematic therapy has made a significant advancement in breast 
cancer patients with regards to disease-free survival and overall survival. (Carlson 2005; 
Goldhirsch, Glick et al. 2005). Using computer-based software, Adjuvant, is proved to be 
helpful in objectively estimating survival and benefit from adjuvant therapy, for early stage 
breast cancer patients, based on the clinico pathlogic features mentioned above (Ravdin, 
Siminoff et al. 2001). However, Adjuvant does not benefit very young women (Olivotto, 
Bajdik et al. 2005). Although, Adjuvant is useful in predicting the outcome for an individual 
patient when the clinico pathologic features are known, those clinic-pathologic features do not 
take into account the biological complexity of an individual’s tumour. Therefore, more 
reliable and precise prognostic and predictive models are needed to estimate what Adjuvant 
therapy should be offered to an individual patient. 
 
1.5.3 Advanced breast cancer 
 
Patients with established metastatic (i.e. advanced) disease may require endocrine therapy, 
chemotherapy and radiotherapy. The treatment is not curative but may be of great palliative 
benefit and consistent often with many years of good-quality life. 
 
High levels of oestrogen receptors (ER) and progesterone receptors (PR) in their tumour have 
greater chance of responding to endocrine treatments. Endocrine therapy is usually tried first 
in patients with characteristics indications to respond and who do not have immediately life-
threatening disease (Clark 2009). On the other hand, chemotherapy is used for patients who 
are unlikely to respond to hormonal treatment or who fail to respond to endocrine therapy or 
who require a rapid response if at risk such as in liver or respiratory failure cases. If chosen 
carefully, chemotherapy can provide good-quality palliation and prolongation of life (Clark 
2009). 
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1.6 Molecular intrinsic subtypes of breast cancer 
 
Breast cancer is a heterogeneous and phenotypically diverse disease. Breast tumours are 
characterised by cellular and molecular heterogeneity and large number of genes potentially 
involved in controlling cell growth, death, and differentiation. Some cancers such as Lymph 
node metastases (Fisher, Costantino et al. 1993), histologic grade (Elston and Ellis 1991), 
expression of steroid and growth factor receptors (Vollenweiderzerargui, Barrelet et al. 1986; 
Torregrosa, Bolufer et al. 1997), estrogen-inducible genes like cathepsin D (Foekens, Look et 
al. 1999), protooncogenes like ERBB2 (Slamon, Godolphin et al. 1989), and mutations in 
the TP53 gene (Bergh, Norberg et al. 1995; Borresen, Andersen et al. 1995) have been 
correlated to prognosis. However, individual prognostic factors provide limited information 
about the cellular changes induced by the disease. For example, removal of ovaries used to be 
considered as therapeutic in the past, which was successful in some patients, but not others. 
This shows that the prognostic value of many of these parameters may mislead the 
interpretation (Howat, Barnes et al. 1983; Battaglia, Scambia et al. 1988). It has been shown 
that correlating tumour cell gene’s cDNA microarrays with specific features of phenotypic 
variation might provide better understating of the taxonomy of cancer (Golub, Slonim et al. 
1999; Alizadeh, Eisen et al. 2000; Perou, Sorlie et al. 2000; Hedenfalk, Duggan et al. 2001).  
These observations emphasize the importance of studying genetic basis of this disease to gain 
a better understanding.  
 
Characterization (profiling) of breast cancers has advanced significantly since the turn of the 
millennium due to the development of sophisticated technologies. These include gene 
expression arrays, which permit simultaneous measurement of thousands of genes to create a 
molecular portrait of the tumour. Gene-expression profiling has helped in identifying breast 
cancer molecular subtypes that have distinct behaviour and response to therapy; and in the 
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development of prognostic and predictive molecular signatures. These in turn, have resulted 
in a better understanding of the biological heterogeneity of breast cancer. Microarray analyses 
on breast cancers have identified gene expression profiles able to separate tumour classes 
associated with patient survival (Sorlie, Tibshirani et al. 2003; Wang, Klijn et al. 2005).  
 
Several studies on genome-wide expression patterns in cancer types, including lymphoma, 
breast, lung, liver, ovarian and soft tissue sarcomas have been carried out over the years. A 
common feature of these studies has been the emergence of tumour subtypes with distinct 
gene expression patterns for each subtype. The differences in gene expression patterns among 
these subtypes are likely to reflect basic differences in the cell biology of the tumours (Sorlie, 
Tibshirani et al. 2003; Sotiriou, Neo et al. 2003). Gene expression profiling, using 
microarrays to which cDNA or oligonucleotide probes are affixed, allows simultaneous 
measurement of the activity (expression) of thousands of genes in a breast cancer cell.  
 
Gene expression arrays represent the level of expression of a group of genes in a semi-
quantitative manner by comparing the level of messenger RNA (mRNA) to that of the mRNA 
of the same gene from a reference sample.  
 
The two main types of molecular profiling techniques commonly used in the laboratory are 
“supervised” and “unsupervised” analyses. In supervised analyses, the gene sets are designed 
to differentiate tumours by a defined clinical endpoint; as such, the subtypes of cancer can be 
identified based exclusively on the clinical data. Prognostic molecular profiles (prognosis 
signatures) are examples of supervised analyses (Bair and Tibshirani 2004). 
Unsupervised analysis (clustering) permits examination of gene expression patterns regardless 
of clinical endpoints and reflects inherent biologic differences. This approach does not use 
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any of the clinical information about the patient and therefore the subgroups are identified 
only by using the gene expression data (Bair and Tibshirani 2004). 
In addition, there is the semi-supervised analysis which combines both gene expression data 
and clinical data. Clinical data is used to identify a list of genes that correlate with the clinical 
variables of interest and then unsupervised clustering techniques are applied to this subset of 
the genes (Bair and Tibshirani 2004). An example for the semi-supervised is the "intrinsic" 
subtypes. 
 
1.6.1 Intrinsic subtypes of breast cancer  
 
The intrinsic subtypes can generally be classified into two groups in relation to the expression 
of hormone receptor-related genes (Sorlie, Perou et al. 2001). Gene expression studies have 
identified several distinct breast cancers within these intrinsic subtype groups. The main 
subtypes are as follow: estrogen receptor (ER)-negative tumours: basal-like, human epidermal 
growth factor receptor-2 (HER2)-enriched and normal-like; and ER-positive tumours: luminal 
A and luminal B. A sixth breast cancer subtype, termed Claudine-low, has also been identified 
(Carey, Dees et al. 2007) as well as a Luminal C subtype (Sorlie et at. 2001). These subtypes 
differ markedly in prognosis and in the therapeutic targets they express. It is agreed that the 
first three are the major subtypes (Carey, Dees et al. 2007). The list of genes that differentiates 
the different subtypes is called the intrinsic list. It is made up of several clusters of genes 
relating to ER expression. 
 
It has been found that ER-positive and ER-negative are two biologically different breast 
cancers and may derive from different progenitor cells.  
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1.6.1.1 The luminal cancers, A and B 
 
These are so called because they are characterized by expression of genes similar to that 
expressed by normal breast luminal epithelial cells, and may overlap with ER-positive breast 
cancers. They typically express luminal cytokeratins 8 and 18. These are the most common 
subtypes that make up the majority of ER-positive breast cancers, and are characterized by 
expression of ER, PR, and other genes associated with ER activation. 
 
Luminal A and luminal B have some important molecular and prognostic distinctions.  
 Luminal A tumours, which probably make up about 40 percent of all breast 
cancers, usually have high expression of ER-related genes, low expression of the 
HER2 cluster of genes, and low expression of proliferation-related genes (Fan, Oh 
et al. 2006; Hu, Fan et al. 2006). Luminal A tumours carry the best prognosis of all 
breast cancer subtypes (Voduc, Cheang et al. ; Sorlie, Perou et al. 2001; Sorlie, 
Tibshirani et al. 2003; Sotiriou, Neo et al. 2003; Loi, Haibe-Kains et al. 2007). 
 The less common (about 20 percent) luminal B tumours have relatively lower 
expression of ER-related genes, variable expression of the HER2 cluster, and 
higher expression of the proliferation cluster. Luminal B tumours carry a worse 
prognosis than luminal A tumours (Voduc, Cheang et al.) and with poor prognostic 
of 70-genes signature (Fan, Oh et al. 2006). Most luminal B cancers have high 
Recurrence Scores. 
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1.6.1.2 HER2-enriched  
 
The HER2-enriched subtype (previously known as HER2+/ER-) makes up about 10 to 15 
percent of breast cancers. It is characterized by high expression of the HER2, proliferation 
gene clusters, and low expression of the luminal cluster. For this reason, these tumours are 
typically negative for ER and PR, and positive for HER2. It is important to note that this 
subtype comprises only about half of clinically HER2-positive breast cancer. The other half 
has high expression of both the HER2 and luminal gene clusters and fall in a luminal subtype. 
In the era before HER2-targeted therapy, this subtype carried a poor prognosis (Voduc, 
Cheang et al.). This adverse natural history has been markedly affected by therapeutic 
advances in HER2-directed therapy. 
 
1.6.1.3 Basal-like 
 
The basal-like subtype makes up about 15 to 20 percent of breast cancers. It is so called 
because of some expression similarities to that of the basal epithelial cells. It is characterized 
by low expression of the luminal and HER2 gene clusters. For this reason, these tumours are 
typically ER-, PR-, and HER2-negative on clinical assays. It is therefore, nicknamed "triple-
negative" (Olopade and Grushko 2001; Sorlie, Tibshirani et al. 2003; Foulkes, Brunet et al. 
2004).  
Basal-like breast cancer has unique risk factors. The most intriguing is that over 80 percent of 
cancers arising in women born with a mutation in the breast cancer gene 1 (BRCA1), early 
onset gene, are basal-like (Olopade and Grushko 2001; Sorlie, Tibshirani et al. 2003; Foulkes, 
Brunet et al. 2004). Nevertheless, most basal-like breast cancers are sporadic, and the BRCA1 
gene and protein appear intact in these tumours. A commonly held assumption, but unproven, 
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is that the BRCA1 pathway is abnormal in sporadic basal-like breast cancer. This may have 
therapeutic implications since this pathway is important in DNA repair.  
 
There is a notable association between the basal-like subtype, race and age. Population-based 
studies suggest that the basal-like subtype is overrepresented in breast cancer in African-
American women, and developing during the premenopausal years (Fan, Oh et al. 2006; 
Millikan, Newman et al. 2008; Lund, Trivers et al. 2009; Parker, Mullins et al. 2009). This 
may explain its prevalence among young African-American women. Basal-like breast cancer 
is known to have poor prognosis; and this may contribute in part to the worse outcomes 
experienced by African-American women with breast cancer (Voduc, Cheang et al.). 
Fortunately, studies suggest that basal-like breast cancers are sensitive to modern 
chemotherapy (Rouzier, Perou et al. 2005; Carey, Dees et al. 2007). However, the absence of 
targeted therapy, of known effectiveness, to this subtype remains a real obstacle to improving 
outcomes. 
 
1.6.1.4 Claudin-low 
 
This newly described subtype is found in non-basal triple-negative breast cancers, which is 
uncommon but interesting because of its expression of epithelial-mesenchymal transition 
genes and characteristics reminiscent of stem cells. 
 
This subtype comprises a minority of triple-negative breast cancers. It is characterized by low 
to absent expression of epithelial cell-cell adhesion genes (claudin 3, 4 and 7, E-cadherin), 
differentiated luminal cell surface markers (EpCAM and MUC1) and enrichment for 
epithelial-to-mesenchymal transition markers, immune response genes and cancer stem cell-
like features (CD44+/CD24-, high ALDH1A1) (Carey, Dees et al. 2007). In contrast to basal-
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like breast cancers, claudin-low tumours appear to be slower growing and, with features of 
mesenchymal and mammary stem cells, of different oncogenic origin. 
 
1.6.1.5 Normal-like 
 
This subtype was one of the first subtypes identified by gene expression arrays and 
consistently appears in breast cancer clusters. It is typified by similar gene expression pattern 
as normal breast cells, and thus remains enigmatic as to whether it represents a separate 
subtype or a technical artefact introduced by low tumour cell composition of the sampled 
specimen. 
 
The challenge is how to define the intrinsic subtypes of breast cancer. They have been 
identified using cluster analysis of gene expression data from frozen banked tissue. This 
method uses fixed tissues and has poor reproducible classification. Recently, a new assay 
(PAM50) has been developed. It is a 50-gene reverse transcription-polymerase chain reaction 
(RT-PCR) based method, and is derived from a 500-gene intrinsic list. It can be performed on 
fixed tissue but has not yet been sufficiently validated for clinical use (Parker, Mullins et al. 
2009). Others methods include immunohistochemical surrogates for the intrinsic subtypes. 
These are reasonable but also have not been validated, and the simplest schema using clinical 
assays for ER, progesterone receptor (PR), and HER2 misclassify a significant proportion of 
tumours (Carey, Perou et al. 2006). 
 
1.6.2 Prognosis of intrinsic subtypes 
 
The intrinsic subtypes were developed to identify relevant biology, not for prognosis. 
However, in multiple independent datasets, these subtypes correlate with prognosis. In 
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general, patients with the luminal A subtype have the best prognosis; patients with the other 
major hormone receptor-positive subtype, luminal B, suffers a significantly worse outcome. 
In a population-based study of nearly 500 tumours using immunohistochemical proxies for 
the subtypes, the best outcome was observed among patients with luminal A tumours 
compared with the other subtypes, and the worst outcome was seen among basal-like breast 
cancers (Carey, Perou et al. 2006). Both the basal-like and HER2-enriched subtypes have the 
worst survival chances, at least until recently. The HER2-targeting has altered the outcome for 
the HER2-enriched subtype and HER2-positive luminal cancers.  
 
In summary, clustering or unsupervised classification approaches are used to build groups of 
genes, with related expression patterns, and separate genes into highly similar groups without 
predefined group labels. Clustering is a common method of gene expression data analyses. 
Most researchers use clustering methods based on similarity/dissimilarity, distance measure 
and hierarchical clustering. Several studies have concluded that using gene-expression 
profiling would be potentially crucial as a new prognostic and predictive tool. However, 
validation of the clinical use of this technology, at the moment, is still a major challenge for 
microarray studies, particularly with clinical implications.  
 
The conflicting number of clusters reported by different studies may be due to the number of 
samples analysed and/or the method of analysis in identifying the overlapping between cluster 
classes. Almost all previous studies applied Hierarchical clustering method, and no attempts 
have been made to use alternative clustering methods that might be more helpful in clearly 
identifying the clusters, and the present study aimed at exploring the possibility of using 
combined clustering analysis methods to enhance the identification accuracy. 
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Chapter Two 
 
2 OBJECTIVES OF THE STUDY  
 
Breast cancer patients with the same diagnostic and clinical prognostic profile can have 
markedly different clinical outcomes. Classification of breast cancer based on gene expression 
profiling captures the molecular complexity of tumours. Patterns that distinguish subtypes 
further can provide a more refined stratification of the patients compared to individual tumour 
markers Hu et al., (2006). Current classifications assign a patient’s gene expression signature 
to a single class (i.e. subtype). This means that all patients in a subtype should show similar 
expression patterns. Although this has been considered generally true, it is now recognised 
that a reason for relapse or an adverse response to therapy is that some patients normally do 
not clearly show typical symptoms of one subtype. Such patients may be on the borderline of 
a subtype, may show symptoms of more than one subtype, or there are other subtypes 
currently unknown.  
 
This study aims at further exploring the characters of novel breast cancer genes (intrinsic 
genes) that have been previously identified and to refine the classification of breast cancer 
subtypes through advanced gene expression data analyses. The primary aim of this study is to 
do a new analysis by combining two known different clustering methods; (i.e. Hierarchical 
clustering and Self-organizing maps (SOM)). The data used in the current analysis method 
were those reported by Hu et al (2006). The training data contains 259 samples (patients) 
representing five subtypes of cancer (Luminal A, Luminal B, HER2-enriched, Basal-like, and 
Normal-like); and the 306 genes identified by Hu et al., (2006) and used to obtain a 
corresponding set of five class centroids using hierarchical clustering (Table  3.1). 
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The proposed new approach may help: (i) Study characteristic spread of gene expression 
patterns within a predefined subtype. This will provide more clarity into the variability within 
a subtype. (ii) Identify similarity/closeness and/or overlapping of subtypes which may help 
identify patients who cannot be clearly categorised into a specific subtype. This can help in 
choosing the appropriate treatment.  
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Chapter Three 
 
3 MATERIALS AND METHOD 
 
Methods used previously by four main investigating groups were adopted as a base line for 
the analysis in the present study. A brief description of the work of these groups is as follows: 
Sorlie et al (2001) studied 85 tissue samples in which tumour specimens contained more than 
50% tumour cells and the mRNA microarrays for those cells were processed. They selected 
456 cDNA clones from an 8,102 intrinsic gene list as representatives for Basal-like, ERBB2+, 
Normal Breast-like, Luminal Subtype C, Luminal Subtype B and Luminal Subtype A. Those 
genes were with significantly greater variation in expression between different tumours than 
between paired samples from the same tumour. This measure was taken to represent inherent 
properties of the tumours themselves rather than just differences between different samplings. 
They concluded that relating gene expression patterns to clinical outcomes is a key issue in 
understanding the biological diversity of the tumours, and this will improve the chances of 
choosing the suitable type of treatment.  
Later, Sorlie et al., (2003) conducted a study to further refine the previously defined (Sorlie et 
al., 2001) subtypes of breast tumours that have distinct patterns of gene expression. They used 
Hierarchical (unsupervised) clustering analysis based on expression pattern of 534 intrinsic 
genes. These genes were selected on the basis of the similarity of the expression level. The 
results of the study supported the concept that the studied breast tumour subtypes represent 
biologically distinct disease entities. 
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Van't Veer et al. (2002) used DNA microarray analysis on primary breast tumours of 117 
patients, and applied supervised classification to identify a gene expression signature strongly 
predictive of a short interval to distant metastases in patients without tumour cells in local 
lymph nodes at diagnosis.  
Approximately 5,000 genes were selected out of 25,000 genes because they are significantly 
regulated in more than 3 tumours out of 78. These selected genes were clustered on the basis 
of their similarities. They suggested that the tumours can be divided into two types on the 
basis of this set of significant genes. The first type is a good prognostic (i.e. related to low 
metastasis risk) and the second type is a poor prognostic (i.e. associated with a high 
metastasis risk). Their finding of separating tumour classes associated with patient survival 
supported those previously reported by Sorlie et at. (2001), but they extended the work to 
gene expression (or genetic profile) associations with survival in an untreated, node negative 
cohort. In their work to identify reliable good and poor prognostic tumours they used a 
powerful three-step supervised classification method, similar to those used previously by 
(Gruvberger, Ringnér et al. 2001; He and Friend 2001; Khan J 2001). The correlation 
coefficient of the expression for each gene with disease outcome was calculated. It was found 
that 231 genes were significantly associated with disease outcome. The 231 genes were then 
rank-ordered on the basis of the magnitude of the correlation coefficient. This was followed 
by optimizing the number of genes in the 'prognosis classifier' by sequentially adding subsets 
of 5 genes from the top of this rank-ordered list and evaluating its power for correct 
classification using the 'leave-one-out' method for cross-validation. The accuracy improved 
until the optimal number of marker genes was reached, which was 70 genes. Their results 
showed that the gene expression profile outperformed the available clinical parameters, at the 
time, in predicting disease outcome. Their findings provided a strategy to select patients who 
would benefit from adjuvant therapy.  
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Sotiriou et al. (2003) selected 99 patients out of 700 patient population and the overall 
survival for this group was adjusted for standard prognostic factors of tumour size and nodal 
status comparable to the population. They conducted a study of comprehensive gene 
expression patterns generated from cDNA microarrays obtained with a 7,650-feature 
microarray (using unsupervised hierarchical clustering approach) and correlated that with 
detailed clinico-pathological characteristics and clinical outcome in the group of 99 node-
negative and node-positive breast cancer patients. Gene expression patterns were found to be 
strongly associated with estrogen receptor (ER) status and to be the most important 
discriminator of expression subtypes, but moderately associated with grade, and not 
associated with menopausal status, nodal status, or tumour size. Hierarchical cluster analysis 
segregated the tumours into two main groups based on their ER status, which correlated well 
with basal and luminal characteristics. Their findings were in strong agreement with the 
findings of Perou et at. (2000), Sorlie et at. (2001) and Van't Veer et al. (2002) that the ER 
biology plays a central role in breast carcinogenesis defining the configuration of the final 
tumour.  
 
The conditions and outcomes of the studies mentioned above have been used by Hu et al. 
(2006) who conducted breast cancer microarray analyses and subtype clarification study on a 
set of 259 breast cancer samples, represented by 306 expressed genes. This dataset was 
collected from the above four different studies (Table  3.1). These are ‘Gene expression 
patterns of breast carcinomas distinguish tumour subclasses with clinical implications’ 
(Sorlie, Perou et al. 2001), ‘Gene expression profiling predicts clinical outcome of breast 
cancer’ (van 't Veer, Dai et al. 2002), ‘Repeated observation of breast tumour subtypes in 
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independent gene expression datasets’ (Sorlie, Tibshirani et al. 2003) and ‘Breast cancer 
classification and prognosis based on gene expression profiles from a population-based 
study’(Sotiriou, Neo et al. 2003). 
The collected data was pooled and analysed by Hu et al. (2006) to define intrinsic subtypes by 
utilising pathological/clinical data as well as gene expression data. They first evaluated the 
datasets independently, and then combined them to find 306 breast genes which were 
analysed using the hierarchical clustering method. Hu et al. (2006) created a single data table 
from these four sets as follow: 
i. Firstly, identifying the common genes present across all four microarray datasets 
(2800 genes).  
ii. Secondly, Using Distance Weighted Discrimination (DWD) to combine these four 
datasets (Benito, Parker et al. 2004).  
 DWD is a multivariate analyses tool that performs statistical corrections to 
reduce systematic biases resulting in separate datasets. It then makes a global 
adjustment to compensate for these biases: in essence, each separate dataset 
is a multi-dimensional cloud of data points. It takes two point clouds and 
shifts one, such that it more optimally overlaps the other.  
iii. Finally, they determined that 306 of the 1300 unique intrinsic genes were present in 
the combined test set and performed a hierarchical clustering analysis. 
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Table ‎3.1: The combined datasets of Sorlie et al. (2001; 2003), Van't Veer et al. (2002) and Sotiriou et al. 
(2003) arranged by Hu et al (2006).  
Microarray 
type 
Validation Informative 
genes 
Metastasis 
determinants 
References 
 
cDNA Independent 
datasets 
306 genes Luminal A, Luminal B, 
HER2-enriched, Basal-like, 
and Normal-like 
Hu et al., 
(2006) 
cDNA Independent 
training set 
 
99 genes invasive ductal carcinomas; 
46 individuals were node 
negative and 53 were node 
positive  
Sotiriou, et al., 
(2003). 
cDNA Crossvalidation 
 
534 intrinsic 
genes 
Repeated finding in 
independent datasets  
Sorlie et al., 
2003 
Oligonucleotide  
 
Independent 
training set 
70 genes ‘Good signature’ is related 
to low metastasis risk; a 
‘poor signature’ is 
associated with a high 
metastasis risk.  
Van't Veer et 
al., (2002) 
cDNA  456 ‘intrinsic’ 
genes 
‘Luminal A’ tumours have 
a better outcome than 
‘luminal B’ tumours. Worst 
outcome is for ‘basal-like’ 
and ‘ERBB2+’ tumours 
Sorlie et al., 
(2001) 
 
 
The work of Hu et al., (2006) identified the five main subtypes corresponding to the 
previously defined HER2+/ER-, Basal-like, LumA, LumB and Normal Breast like tumour 
groups (Perou, Sorlie et al. 2000; Sorlie, Perou et al. 2001). This type of analysis provides 
more statistical power to perform multivariate analyses. It would also yield more meaningful 
results because any findings would need to be shared/present across all four datasets.  
 
The finding of Hu et al., (2006) is considered as the starting point for this proposed study. The 
Matlab 5 Toolboxes used to investigate the datasets in this study are: SOM Toolbox for SOM 
and Statistics Toolbox for both Ward and Hierarchical clustering. SOM Toolbox can be 
downloaded free of charge under the GNU General Public License from 
http://www.cis.hut.fi/projects/somtoolbox.  
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3.1 Methods of analyses 
 
In this study, after a pilot study to explore the most highly influential genes (potential 
markers) in each subtype, we used a new approach of analyses by combining two pairs of 
analyses methods (Hierarchical-Ward and SOM-Ward clustering) to: 
 Diagnostic markers for each subtype (pilot study). 
 Validate the clusters found by the original authors Hu et al., (2006). 
 Find relationship or similarity between subtypes to identify subtypes that can mask 
each other. 
 Identify possible new cancer subtypes. 
 
Three specific methods are going to be used in this study in an in-depth investigation of 
tumour subtypes: Hierarchical clustering, Self-organizing maps (SOM) and Ward method and 
with these three methods, it will be possible to display differences more clearly between the 
subtypes than using only one method. These methods are employed after an initial pilot study 
involving the most significant genes. A summary of these methods is as follows:  
 
3.1.1 Ward Method 
 
In Statistics, Ward method uses an analysis of variance approach to evaluate the distances 
between clusters. Ward's minimum variance method is a special case of the objective function 
approach originally presented by (Ward 1963). Ward suggested a general agglomerative 
hierarchical clustering procedure that, in general, is regarded as very efficient; however, it 
tends to create clusters of small size, where the criterion for choosing the pair of clusters to 
merge at each step is based on the optimal value of an objective function. To illustrate the 
procedure, Ward used the example where the objective function is error sum of squares, and 
this example is known as Ward's method or more precisely Ward's minimum variance 
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method. In brief, this method attempts to minimize the Sum of Squares (SS) of any two 
(hypothetical) clusters that can be formed at each step (Ward 1963). Ward method works as 
follow: 
 
 Uses an analysis of variance approach to evaluate the distances between 
clusters. 
 Attempts to minimize the Sum of Squares (SS) of any two (hypothetical) 
clusters that can be formed at each step. 
 
     
     
     
         
 
 
 
 
Where   and   denote two specific clusters nr and ns denote the number of data 
points in the two clusters and    and    denote the centres of gravity of the 
clusters;      is the Euclidean norm. 
  
 
 The mean and cardinality of the new cluster built as a product of the merger 
step is computed as follows 
 
   
       
 
     
                   
  
              
 
When Ward method used on a trained SOM (Section 3.1.3), the homogeneity of clusters 
within the map is achieved by merging only neurons and clusters that are neighbours in the 
map (Samarasinghe 2007). Ward method helps to find the optimum cluster structure that 
indicates the best level of clustering. This method computes the likelihood of various numbers 
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of clusters from which the most appropriate number of clusters can be obtained based on a 
likelihood index defined as 
 
            
 
  
 
       
         
  
 
  
 
   
     
  
 
Where    is the distance between the centres of the two cluster to be merged in 
the current step, and      and      are the distance between merged clusters in 
the previous step and the step earlier than the previous.    is the number of 
cluster left. 
 
3.1.2 Hierarchical clustering method 
 
Hierarchical clustering (connectivity based clustering) is one of the most straightforward 
methods among numerous ways in which clusters can be formed. It is based on the core idea 
of objects being more related to nearby objects than to objects farther away. It can be either 
agglomerative (aggregating single patient into clusters) or divisive (dividing complete data set 
into partitions) (Johnson's 1967).  
 
Agglomerative hierarchical clustering considers each case as a cluster. Any two objects that 
have the smallest value on the distance measure (or largest value if similarities are used) are 
joined into a single cluster. Either a third patient  is added to this cluster that already 
containing the two objects, or a new cluster is formed by merging two new other objects. At 
each step, individual objects are added to existing clusters, two individuals are combined, or 
two existing clusters are combined.  
 
The distance between two clusters with more than one patient in a cluster can be defined in 
different ways. For example, average distances between all pairs of patients formed by taking 
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one member from each of the two clusters in turn and calculating the distance to other 
members to find the average distance. Or the largest or smallest distance between two patients 
that are in different clusters can be taken. Computing methods to measure the distance 
between clusters are available; however, different methods suffer from producing different 
solutions.  
 
The distance between sets of observations as a function of the pairwise distances between 
observations is determined by linkage criteria.  
The linkage function uses the distance information generated to determine the proximity of 
objects to each other. Once the proximity between objects in the data set has been computed 
the objects are paired into binary clusters, and the newly formed clusters are grouped into 
larger clusters until a hierarchical tree is formed. Different distances, different clusters will 
form, what is known as the dendrogram. A dendrogram is a tree diagram frequently used to 
illustrate the arrangement of the clusters produced by the hierarchical clustering. It is a useful 
approach to illustrate the clustering of genes or samples in Computational Biology. 
 
To form clusters using a hierarchical cluster analysis, the following must be identified: a 
criterion to determine the similarity (or distance) between patients (such as Euclidean 
distance); a criterion to determine the merging of identified clusters at consecutive steps (such 
as minimum variance); and selecting the number of clusters to represent a particular dataset. 
The Ward method can be applied with hierarchical clustering to find the optimal number of 
clusters in the dendrogram.   
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3.1.3 Self-organizing maps (SOM) 
 
The self-organizing map (SOM) is an artificial neural network algorithm used to visualize and 
interpret large high-dimensional datasets. This helps us to understand these high dimensional 
data by organising them on a map of reduced dimensions. The learning process is competitive 
and unsupervised. The components of SOMs are nodes or neurons that are usually arranged in 
a two-dimensional hexagonal or rectangular grid. A neuron is represented by a weight vector 
with the same dimension as the input vector and neuron weights are initially set to small 
random value. Neurons in a trained map represent the centre of gravity of a cluster input 
vectors. Self-organizing maps operate in two modes: training to build the map using input 
examples, and mapping to automatically classify a new input vector. The Euclidean distance 
is the most commonly used method to determine the neuron with the shortest distance to an 
input, called “the winner”. SOMs preserve topological properties of the input space. They use 
a neighbourhood feature to adjust neuron weights, not only of the winner neurons with the 
closest distance to an input vector, but also of their neighbour neurons. Furthermore, it 
presents mapping from a higher dimensional input space to a lower dimensional map space. 
This makes it possible to visualise the organisation of input vectors. Learning in self-
organizing maps aims to specialise parts of the network to respond similarly to certain input 
patterns. 
Figure 1 gives a pictorial example of a trained SOM; where the darker colour represents the 
area of larger distance between neurons (i.e., between weights). Smaller distances are 
represented by the lighter colour. This shows that the white areas represent different clusters 
and the black lines represent the boundaries between them.  
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Figure 1: Self-organizing maps 
 
 
3.1.3.1 Self-Organizing Map algorithm 
 
Assume that some sample datasets have to be mapped onto an SOM. The set of input samples 
is described by a real vector     
 
x(t)‎Є‎Rn     [5] 
Where (t) is the index of the sample, or the discrete-time coordinate. Each node (i) in the map 
is represented by a weight vector    
mi(t)‎Є‎R
n
     [6] 
which has the same number of elements as the input vector  x(t). The SOM algorithm 
performs an iteration process, where the initial values of the components of the weight 
vector, mi(t), may be selected at random. In practical applications, however, the model 
vectors are more profitably initialized in some orderly fashion, e.g., along a two-dimensional 
subspace, spanned by the two principal eigenvectors of the input data vectors (Kohonen 
1995c). Additionally, a batch version of the SOM algorithm may also be used (Kohonen 
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1995c). The mi(t) which matches best with x(t) in some metric, is thought to map that input 
into its location. The self-organizing algorithm creates the ordered mapping as a repetition of 
the following basic tasks: 
i. An input vector x(t) is compared with all the weight vectors mi(t). The best-matching 
unit (node) on the map is selected. It is often called the winner. 
ii. The weight vectors of the winner and a number of its neighbouring nodes in the array 
are changed towards the input vector according to the learning principle specified 
below. 
The basic idea behind the learning process of SOM is that, for each sample input vector x(t), 
the winner and the nodes in its neighbourhood are brought closer to x(t) in the input data 
space. During the learning process, individual changes may be contradictory. However, the 
net outcome in the process is that ordered values for the mi(t) emerge over the map. If the 
number of available input samples is restricted, the samples must be presented iteratively to 
the SOM algorithm. 
 
Adaptation of the weight vectors in the learning process may take place according to the 
following equations: 
mi(t + 1) = mi(t)‎+‎α(t)‎Nc(t) [x(t) – mi(t)]‎‎‎‎‎‎‎for‎each‎i‎Є‎Nc(t),  [7]  
Otherwise, 
mi(t + 1) = mi(t)      [8] 
where t is the discrete-time index of the variables, the factor α(t)‎ Є‎ [0,1] is a scalar that 
defines the relative size of the learning step (learning rate), and Nc(t) specifies the strength of 
the weight adjustment for the neighbourhood around the winner in the map array. 
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The radius of the neighbourhood, at the beginning of the learning process, is fairly large. 
However, it is made to shrink during learning. This ensures that the global order is obtained 
already at the beginning, whereas towards the end, as the radius gets smaller, the local 
corrections of the model vectors in the map will be more specific. Gaussian neighbour 
strength as a function of radius is commonly used. The learning rate α(t) also decreases during 
learning. 
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Chapter Four 
 
4 RESULTS 
4.1 Pilot investigation  
 
An initial analysis was conducted on 306 genes involving 5 types of cancer across 249 
samples (patients). The set of data was the same as that used in the study of Hu et al. (2006). 
The purpose of the analysis was to identify genes that might be significantly related to each 
individual subtype, by using a preliminary exploration of the 306 genes (described below). If 
a gene is highly significant in one subtype but not significant in any other subtype, this can be 
used as a unique marker exclusive to that subtype. 
 
The 306 genes were plotted against the gene expression level of each patient under each 
subtype. The value of the expression level is represented by ratio of (Abnormal/Normal). 
These values can be classified into normal, highly expressed, or highly depressed. Both the 
highly expressed and the highly depressed are indicators of cancer. The data were analysed 
using Matlab software to identify the median expression level of the most significantly 
expressed genes. 
 
The results of the analysis are illustrated in Figure 2. The figure shows that the most 
significantly expressed gene in LumB subtype is Hs.79136 gene, at +1.888 expression level 
(Figure 2a, black colour). The expression level of the same gene (green colour) was +2.225 in 
LumA (Figure 2b), -0.402 in Normal Like (Figure 2c), -1.638 in Her2 (Figure 2d), and -1.063 
in Basal Like (Figure 2e), respectively.  
From these results it is evident that the Hs.79136 gene has significant expression levels, in 
different degrees, across almost all studied subtypes. For example, this gene is more highly 
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expressed in LumA (+ 2.225) than in LumB (+1.888). However, as it is expressed in both it is 
not possible to consider this gene as an indicator of LumA or LumB subtype specifically. 
Same applies to subtypes in which this gene is highly expressed.  
 
 
Figure 2: The median value of the highly expressed gene in LumB (Hs. 79136 in black colour) compared 
to its median expression levels in other subtypes (green colour). 
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Since using one significant gene as a marker was not successful, it was decided to involve 
more genes in the search. The analysis method searched for the six genes with the highest 
expression/inhibition in LumB, LumA, Normal Like, Basal Like, and Her2 as illustrated in 
Figure 3.  Because the intensity of the data hindered the clarity of the outcome, a bar graph 
was chosen to represent the results in this case.  
The six most highly expressed/inhibited genes in LumB were the previously noted Hs.79136, 
Hs.1657, Hs.82961, Hs.396783, Hs.80420 and Hs.425311 which are arranged here in a 
descending order according to their level of expression/ inhibition (Figure 3a). For example, 
Hs. 79136 is more highly expressed than Hs.1657 and so on.  
 
Figure 3a also shows the expression levels of these genes in the other subtypes of cancer. It 
can be seen that genes Hs.79136, Hs.1657, Hs.82961 and Hs.80420 (representing genes No 1, 
2, 3, and 5) are also highly expression/inhibited in subtypes other than LumB and cannot, 
therefore, be considered as specific markers. However, the most important genes in LumB are 
gene number 4 (Hs.396783) and 6 (Hs.425311) which are not significantly 
expressed/inhibited in the other four subtypes and could therefore be potentially useful 
markers for LumB. 
 
When the same method of analysis was applied to LumA, it was observed that Hs.79136, 
Hs.1657, Hs.82961, Hs.89603, Hs.169946 and Hs.390163 genes were the six highly 
expressed/inhibited.  
It was found that Hs.79136 was also highly expressed in this subtype as it was in LumB 
(Figure 3b and Appendix A). Thus, it was concluded that this gene cannot be considered as a 
useful marker to identify LumA. However, it was also observed that only gene number 4 
(Hs.89603 +1.44) and possibly gene numbers 5 and 6 (Hs.169946 +1.36 and Hs.390163 
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+1.14) were the most significant in LumA compared to the other subtypes. These genes, 
unlike gene number 1 (Hs.79136), could therefore be useful as markers for LumA.  
 
In the Normal Like subtype, the six most significantly expressed/inhibited genes were 
identified as Hs.81665 (+1.922), Hs.334562 (-1.75), Hs.77204 (-1.56), Hs.80420 (-1.64), 
Hs.69771 (-1.43) and Hs.433871 (1.34) (Figure 3c and Appendix A). The relative 
expression/inhibition level for these genes in the different subtypes varied. Although genes 
number 2 (Hs.334562) and 4 (Hs.80420) (in Figure 3c) were well expressed/inhibited, but 
they were also obviously present in other subtypes and cannot be considered as useful 
markers.  
The most noticeable observation is that genes number 1 (Hs.81665), 3 (Hs.77204), 5 
(Hs.69771) and 6 (Hs.433871) were very well expressed/inhibited in Normal Like than in 
other subtypes, particularly gene number 6 which can clearly be considered as a unique 
marker for this subtype. 
 
Genes Hs.82961 (-3.35), Hs.169946 (-3.03), Hs.437638 (-2.72), Hs.1657 (-2.5), Hs.26770 
(2.38) and Hs.2256 (2.37) (labelled number 1, 2, 3, 4, 5 and 6, respectively in Figure 3d) were 
highly expressed/inhibited in the Basal Like subtype, although they were also present in the 
other subtypes. The most interesting finding is that genes number 3 and 5 were clearly the 
most dominant in the Basal Like compared to other subtypes. It was also found that gene 
number 5 had no expression in Normal Like subtype. Hence, genes number 3 and especially 
number 5 can be confidently considered as useful markers for the Basal Like subtype. Gene 
number 1 is important in Basal Like subtype but since the same gene is also important in 
other subtypes, the third most significant gene in both LumB and LumA, this gene cannot be a 
useful marker for the Basal Like subtype. 
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In the Her2 subtype two distinctive genes were Hs.446352 (4.161) and Hs.86859 (4.130) 
(genes number 1 and 2 in Figure 3e) which were highly significantly expressed and can be 
regarded as unique markers for this subtype. 
 
A summary of the pilot marker genes found in this analysis is gene in (Table  4.1) with colour 
to make it easier to find out if a gene is found important for more than one subtype.  
 
Table ‎4.1: A summary of the six most significant genes with their expression levels in each subtype. (The 
colour indicates if a gene is significant in more than one subtype). 
No 
LumB LumA Normal Like Basal Like Her2 
Gene Name Expression Gene Name Expression Gene Name Expression 
Gene 
Name 
Expression 
Gene 
Name 
Expression 
1 Hs.79136 1.888 Hs.79136 2.225 Hs.81665 1.920 Hs.82961 -3.350 Hs.446352 4.161 
2 Hs.1657 1.380 Hs.1657 1.640 Hs.334562 -1.750 Hs.169946 -3.030 Hs.86859 4.130 
3 Hs.82961 1.270 Hs.82961 1.460 Hs.77204 -1.560 Hs.437638 -2.720 Hs.1657 -1.754 
4 Hs.396783 1.220 Hs.89603 1.440 Hs.80420 -1.640 Hs.1657 -2.500 Hs.90786 1.210 
5 Hs.80420 -0.978 Hs.169946 1.360 Hs.69771 -1.430 Hs.26770 2.380 Hs.79136 -1.063 
6 Hs.425311 0.976 Hs.390163 1.140 Hs.433871 1.340 Hs.2256 2.370 Hs.298654 1.000 
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Figure 3: The median expression level of the most highly expressed/inhibited six genes in LumB, LumA, 
Normal Like, Basal Like, and Her2 subtypes. 
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4.1.1 Using Visualisation Analysis to identify potential markers 
 
The findings of the pilot analysis were encouraging and justified the involvement of more 
genes that could help further identify other potential markers for the different subtypes in this 
study. Visualisation analysis method was carried out using GGobi software to analyse all the 
306 studied genes simultaneously. The genes were plotted against their expression/inhibition 
levels across all subtypes and ranked from the highest positive to the highest negative value, 
as represented in Figure 4. 
 
 
Figure 4: GGobi software based parallel coordinate plot for the 306 genes across the 249 patients 
representing the 5 subtypes. 
 
The Figure 4 illustrates the complexity of plotting all the genes at the same time. Therefore, 
attempts were made to select the most highly expressed genes visually and label them with 
different colours and then follow their expression/inhibition in the different subtypes, as 
demonstrated in Figure 5. 
 
Figure 5 shows that a gene signature pattern may be more clearly assessed by this method. 
For example, the three most highly significant genes in LumB (yellow colour) were also the 
most highly significant genes in LumA. The first and the second genes were insignificant in 
the Normal Like subtype, slightly inhibited in the Basal Like subtype but significantly 
Genes 
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inhibited in the Her2 subtype. The third significant gene in LumB and LumA was 
insignificant in both the Normal Like and the Her2 subtypes, but was highly significantly 
inhibited in the Basal Like. On the other hand, the fourth highly significant gene (also in 
yellow colour) in LumB was not significant in the other four subtypes. Therefore, this 
analysis indicates that this gene is probably a useful marker for the LumB subtype. The 
signature pattern of these four genes found by this method of analysis match the results 
observed previously when only six genes were plotted at one time (Figure 3). 
 
 
Figure 5: GGobi software displays a parallel coordinates for the 306 genes across the 249 patients 
(subtypes) and highlighting only the most highly expressed genes visually and label them with 
different colours. 
 
Four significant genes were identified in the Normal Like subtype (blue colour), and the 
pattern of these genes’ significance can be inferred as described above. Similarly, three 
significant genes can be identified in the Basal Like subtype (green colour line), and the 
pattern of significance of these genes can be traced in the other subtypes. For the Her2 
subtype, two genes (orange colour line) can obviously be seen as the most significant for this 
subtype compared to their significance in the other subtypes. 
 
Although, the signature pattern of the significant genes confirm the previous results recorded 
when only six genes were plotted at one time (Figure 3), the limitation of the visualisation 
Genes 
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analysis is that the software does not have scaling features. Therefore, care must be practiced 
when interrupting the results. For example, the first significant gene in LumB and LumA 
looks to have similar value in both subtypes, but the six genes analysis method, which is 
scaled, showed that the actual gene expression value was +1.888 in LumB whilst it was 
+2.224 in LumA. To explain further, the first significant gene in LumB can be used as a guide 
for its significance in other subtypes. By drawing a line across the different subtypes we can 
get a visual pattern of this genes’ relative significance.  
 
Another limitation of the visualisation analysis method is that it cannot identify (name) the 
different genes. The patterns from this method however, can be compared/matched with the 
patterns obtained from the six gene analysis method. Through this pattern 
comparison/matching we can name the genes. This study demonstrates that by combining the 
two methods, the patterns can be more confidently confirmed.   
 
From the results above, it can be concluded that the two different forms of data representation, 
although useful, can be of limited advantage in identifying subtypes through the significance 
of expression/inhibition of a greater number of potential marker genes. It is therefore 
necessary to explore other methods of analysis using software that can isolate clusters of 
genes that can be important markers for the subtypes. This was not attempted in this study.   
 
In the next sections, whole gene set (306 genes) obtained by Hu et al. (2006) is subjected to 
deeper investigation using Hierarchical clustering and Self Organising feature Maps (SOM) in 
conjunction with the Ward method to ascertain its efficacy in clustering subtypes.   
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4.2 Replicating original outcomes - Hierarchical clustering 
 
The outcomes of our pilot study have encouraged us to explore the subtype classification 
beyond the investigation of the original researchers. The original researchers’ work was first 
repeated by using the same method of analysis, namely hierarchical clustering method. The 
aim was to compare the outcomes of the current study with the original ones.  
 
The hierarchical method uses different distance metrics. These differ from one another in how 
they measure the distance between clusters. These methods include: average- ‘unweighted 
average distance’, centroid- ‘centroid distance’, complete linkage- ‘furthest distance’, median- 
‘weighted centre of mass distance’, single linkage- ‘shortest distance’, weighted- ‘weighted 
average distance’ and ward- ‘inner square distance’ (Appendix B). The Ward method was 
introduced to the hierarchical clustering method in this study because it employs the inner 
square distance (minimum variance algorithm) which helps representing the data more 
clearly, as illustrated in (Appendix B). The original authors had not mentioned the distance 
metric they used in Hierarchical clustering. 
 
Figure 6 demonstrates that putting the data obtained from the hierarchical method through the 
Ward statistical analysis resulted in identifying the most likely number of clusters. The figure 
also shows that 6 sub-clusters are present with high probability. Furthermore, two clusters are 
also present but with less probability. This means that there are potentially 6 sub-clusters, are 
more than the five clusters found by the original authors.  
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Figure 6: Ward likelihood index of hierarchical method for various numbers of clusters of patients 
(subtypes). 
 
These observations were compared with those of the original authors’ work. Therefore, the 
identified clusters were analysed further to find the distribution of the patients between the 
obtained clusters. The calculated distributions were compared with that of the original 
authors’ results. Our analysis identified the sub-clusters and assigned the appropriate patients 
in each sub-cluster, and then identified the patients that were matched with those in the 
original work of the authors. 
 
Table  4.2 shows the distribution of the patients between two clusters as identified by 
hierarchical method in the present study. The two clusters are shown in Figure 7.  By 
matching the patient numbers (labels) with those numbers in the original authors’ subtypes, 
we found that LumB, LumA and Normal Like subtypes belong to cluster 1 in this work, while 
the Basal Like and Her2 belong to cluster 2. 
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Table ‎4.2: Two clusters obtained from the hierarchical-ward method of the current study. 
 
Current Study 
 
 
Cluster 1 Cluster 2 Total 
No of Patients 161 88 249 
Subtypes LumB, LumA & Normal Basal & Her2  
 
 
The same calculation procedure was followed to identify the distribution of patients between 
the subtypes. Table  4.3 shows the number of patients and their sequence (order of appearance 
in the dataset) in each subtype according to the original authors’ data. When these numbers 
were compared with the numbers identified by the current hierarchical analysis (Appendix C) 
it was found that the patients belonging to LumB, LumA and the Normal Like subtypes 
(representing cluster 1) completely matched (100%) the sequence number reported in the 
original research. The sequence of the patients belonging to Basal Like and the Her2 subtypes 
(representing cluster 2) matched the sequence reported in the original research by only 98% 
and 83%, respectively. The remaining 2% and 17% of patient numbers were located in cluster 
1 in this study. 
 
Table ‎4.3: Matching percentage between original work and current study of hierarchical-ward method. 
 
Original Author's data 
 
 
LumB LumA Normal Basal Her2 
 
No of patients 46 90 19 65 29 249 
Sequence order of 
patient number 
1 to 46 47 to 136 137 to 155 156 to 220 
221 to 
249  
match percentage 100% 100% 100% 98% 83% 
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Figure 7: A dendrogram specifying the two clusters of patients (at cut off point 2727) according to their 
correlation strength. 
 
Although not a strong outcome of our study, five sub-clusters were selected based on cut off 
distance 1050 in order to compare them with the original five subtypes reported by the 
original researchers (Figure 8). It was found that 67% of the patients of LumB were present in 
sub-cluster 1, 30% in sub-cluster 2 and 2% in other sub-clusters of this work (Table 4.4, Table 
4.5 and Appendix C). Similarly, 50% of the LumA was in sub-cluster 3, 43% in sub-cluster 2 
and 7% in sub-cluster 1 of the present work. Likewise, 95% of the Normal Like subtype was 
present in sub-cluster 3 and 5% only in sub-cluster 2. Sub-cluster 4 contained 86%, sub-
cluster 5 contained 12% and the other sub-clusters contained 2% of the Basal Like subtype 
respectively. Finally, 79%, 10% and 10% of the Her2 subtype were in sub-cluster 5, sub-
cluster 3 and other sub-clusters, respectively.  
 
This clearly indicates that the present results have similarities, to varying degrees, to those of 
the original researchers. However, the results also indicate that there is a clear overlap 
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between the subtypes, especially between LumB, LumA and Normal Like subtypes.  As 
shown in Table 4.5, patients from sub-cluster 1 and sub-cluster 3 (belonging to cluster 1 in 
Table  4.2) can overlap with sub-cluster 4 and sub-cluster 5. This confirms the earlier finding 
that were explained in Table  4.2 and Table  4.3 regarding the overlapping of patients between 
the clusters.  
 
Table ‎4.4: Five sub-clusters obtained from the hierarchical-ward method of the current study. 
Hierarchical data analysis 
    
 
Sub-cluster 
1 
Sub-cluster 
2 
Sub-cluster 
3 
Sub-cluster 
4 
Sub-cluster 
5 
Total No of 
patients 
No of 
patients 
40 54 67 57 31 249 
 
 
Table ‎4.5: Matching percentage between original work and current study of the 5 sub-clusters obtained by 
hierarchical-ward method. 
Original authors’ subtype analysis 
    
 
LumB LumA Normal Basal Her2 
Total No of 
patients 
No of patients 46 90 19 65 29 249 
Sequence order of 
patient number 
1 to 46 47 to 136 137 to 155 156 to 220 221 to 249 
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Sub-clu 1 Sub-clu 3 Sub-clu 3 Sub-clu 4 Sub-clu 5 
 
67% 50% 95% 86% 79% 
 
Sub-clu 2 Sub-clu 2 Sub-clu 2 Sub-clu 5 Sub-clu 3 
 
30% 43% 5% 12% 10% 
 
Others Sub-clu 1 Others Sub-clu 1 Sub-clu 1 
 
2% 7% 0% 2% 10% 
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Figure 8: A dendrogram specifying the five clusters of patients (at cut off point 1050) according to their 
correlation strength 
 
Our Hierarchical-Ward analysis showed the possibility of the presence of six sub-clusters 
rather than five. Examining these sub-clusters in depth (Table 4.6, Figure 9 and Appendix C) 
showed that 67%, 30% and 2% of the LumB subtype were in sub-cluster 3, sub-cluster 4 and 
sub-cluster 1 respectively. Further, 43%, 24%, 26% and 7% of the LumA subtype were in 
sub-cluster 4, sub-cluster 1, sub-cluster 2 and sub-cluster 3, respectively. Ninety five percent 
of the Normal Like subtype was in sub-cluster 1 and the remaining 5% was in sub-cluster 4. 
In addition, 86%, 12% and 2% of the Basal Like subtype were found sub-cluster 5, sub-
cluster 6 and sub-cluster 3 in that order. Finally, 79%, 10%, 7% and 3% of the Her2 subtype 
were respectively in sub-cluster 6, sub-cluster 1, sub-cluster 3 and sub-cluster 5. 
 
This analysis shows that there is considerable overlapping between the original five subtypes, 
plus the presence of one extra sub-cluster that has not been identified before. The extent of 
overlapping was characterised by all subtypes except the Basal Like subtype being present in 
sub-cluster 1. Similarly, all subtypes except the Normal Like were present in sub-cluster 3. 
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Furthermore, it was noticed that sub-cluster 1 and sub-cluster 3 were less frequent in the Basal 
Like and the Her2 subtypes than in the LumB, LumA and Normal Like subtypes. 
 
Cluster consisting of the Basal Like and the Her2 subtypes in the two cluster format (Table 
 4.2) overlaps with different sub-clusters in the six sub-cluster format. However, the 
overlapping involving sub-cluster 5 and sub-cluster 6 was unique to Basal Like and Her2 
subtypes. By contrast, overlapping with sub-cluster 4 was unique to the group containing 
LumB, LumA and the Normal Like subtypes.  
The most significant observation was that sub-cluster 2 contained LumA subtype only. 
 
Table ‎4.6: Matching percentage between original work and current study of the 6 sub-clusters obtained by 
hierarchical-ward method. 
 
Original Author's subtypes 
 
LumB LumA Normal Basal Her2 
No of Patients 46 90 19 65 29 
Sequence order of patient numbers 1 to 46 47 to 136 137 to 155 156 to 220 221 to 249 
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Sub-clu 3 Sub-clu 4 Sub-clu 1 Sub-clu 5 Sub-clu 6 
67% 43% 95% 86% 79% 
Sub-clu 4 Sub-clu 1 Sub-clu 4 Sub-clu 6 Sub-clu 1 
30% 24% 5% 12% 10% 
Sub-clu 1 Sub-clu 2 
 
Sub-clu 3 Sub-clu 3 
2% 26% 
 
2% 7% 
 
Sub-clu 3 
  
Sub-clu 5 
 
7% 
  
3% 
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Figure 9: A dendrogram specifying the six clusters of patients (at cut off point 847) according to their 
correlation strength  
 
The above results are now presented in the reverse format to highlight which sub-clusters 
represent which subtype(s).  Table  4.7 shows results for the 5 cluster case. When these sub-
clusters were compared with the 5 original authors’ sub-clusters, it was found that 78%, 15%, 
5% and 3% of LumB, LumA, Her2 and Basal subtypes, respectively were contained in Sub-
cluster 1. LumA, LumB and Normal Like subtypes were contained in sub-cluster 2 at 72%, 
26% and 2%, respectively. In sub-cluster 3 LumA, Normal Like, Her2 and LumB subtypes 
were present at 67%, 27%, 4% and 1%, respectively. Sub-cluster 4 98% contained Basal Like 
subtype and 2% Her2 subtypes. On the other hand, sub-cluster 5 contained 74% Her2 and 
26% Basal like subtypes. 
 
As shown previously, when the Ward analysis method was applied to the results of our 
Hierarchical analysis of the original dataset, it produced a strong likelihood for the presence 
of two clusters that were again divided into six sub-clusters (Figure 9) with the strongest 
likelihood. When the 6 clusters were analysed in terms of the subtypes they contain. It was 
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interesting to observe that cluster 2 (Table  4.2) was divided into two sub-clusters (5 and 6 in 
Table  4.8) that contained the same subtypes that were present in sub clusters 4 and 5 (Table 
 4.7), and more interestingly, with the exact percentages.  
 
Cluster 1 (Table  4.2) was divided into four sub-clusters (1, 2, 3 and 4, Table  4.8). Sub-clusters 
3 and 4 contained the same subtypes and percentages that were present in sub-clusters 1 and 2 
in the 5 clusters analysis (Table  4.7). Similarly, sub-clusters 1 in the 6 sub-clusters analysis 
contained the same subtypes that were contained in sub-cluster 3 in the 5 sub-clusters 
analysis, but with different percentages (Table  4.7). Sub-clusters 2 in the 6 sub-clusters 
analysis contained LumA subtype only. This could indicate that sub-clusters 1 and 2 resulted 
from the division of sub-cluster 3 in the 5 sub-clusters analysis. These results highlight the 
intricate relationship between LumA, LumB and Normal subtypes on one hand and that of 
Basal like and Her2 subtypes on the other, and clustering cannot separate the 5 subtypes 
uniquely.  However, it can be said a patient falling into sub-cluster 2 could be identified as 
LumA with certainty.  Similarly, a patient falling into sub-cluster 5 would highly likely be of 
Basal like subtype.  Sub-cluster 6 would identify a patient to be more likely to be of Her2 but 
there is 25% chance for it to be of Basal-like. Overall, six clusters seems to offer an advantage 
over 5 clusters.  
Table ‎4.7: The distribution comparison between the original five subtypes and the five sub-clusters 
obtained from the hierarchical-ward method in the current study.  
Hierarchical Current data - 5 sub-clusters 
 
Sub-Cluster 
1 
Sub-Cluster 
2 
Sub-Cluster  
3 
Sub-Cluster 
4 
Sub-Cluster  
5 
Total 
No of 
patients 
No of patients 40 54 67 57 31 249 
 
LumB (78%) LumA (72%) LumA (67%) Basal (98%) Her2 (74%) 
 
 
LumA (15%) LumB (26%) Normal (27%) Her2 (2%) Basal (26%) 
 
 
Her2 (5%) Normal (2%) Her2 (4%) 
   
 
Basal (3%) 
 
LumB (1%) 
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Table ‎4.8: The distribution comparison between the original five subtypes and the six sub-clusters 
obtained from the hierarchical-ward method in the current study. 
Hierarchical Current data - 6 sub-clusters 
 
 
Sub-Cluster 
1 
Sub-Cluster 
2 
Sub-Cluster 
3 
Sub-Cluster 
4 
Sub-Cluster 
5 
Sub-Cluster 
6 
No of patients 44 23 40 54 57 31 
 
LumA (50%) 
LumA 
(100%) 
LumB (78%) LumA (72%) Basal (98%) Her2 (74%) 
 
Normal 
(41%)  
LumA (15%) LumB (26%) Her2 (2%) Basal (26) 
 
Her2 (7%) 
 
Her2 (5%) Normal (2%) 
  
 
LumB (2%) 
 
Basal (3%) 
   
 
 
4.3 Analysis with Self-Organizing Maps (SOM): 
 
In the SOM analysis, patients are clustered to assess their separability into groups. A patient is 
represented by an input vector that contains expression ratios for the 306 genes.  A 25 neuron 
map was trained in this study in batch mode. Figure 10 shows a partial pictorial view of SOM 
with only 2 inputs (2 genes) with green dots indicating the location of inputs and the blue 
indicating the corresponding components of the weight vectors. Results shown are after 200 
iterations of the batch algorithm and indicate that the map is reasonably distributed through 
the input space. The SOM has spread across the input space as indicated by the map neurons 
connected to their neighbours with red lines. 
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Figure 10: SOM plot of the inputs (green dots) and weights (blue) showing how the SOM spans the input 
space. Neighbour neurons are connected by red lines. 
 
 
Figure 11 shows the U-matrix representation of the Self-Organizing Map that visualizes the 
SOM Neighbour Distances between the neurons (clusters) of the 249 samples. The blue 
hexagons represent the neurons and the red lines connect neighbouring neurons. The distance 
between the adjacent clusters is calculated and presented with different colours between the 
adjacent nodes. A darker colour between the clusters corresponds to a larger distance and thus 
a larger gap between the weights in the input space. A lighter colour between the neurons 
signifies that the weights vectors are closer to each other in the input space. Lighter areas can 
be thought of as clusters and dark areas as cluster separators. This can be a helpful 
presentation when one tries to find clusters in the input data without having any a priori 
information about the clusters. 
 
According to Figure 11, there can be potentially 2 to 3 solid clusters that can be further 
broken down to smaller clusters which could possibly represent subtypes. Figure 12 shows 
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how many of the training data are associated with each of the neurons (cluster centres). The 
maximum number of hits associated with any neuron is 35. Thus, there are 35 inputs or 
patients in that cluster. 
 
 
Figure 11: SOM layer showing neurons as blue and their direct neighbour relations with red lines. The 
neighbour patches (potential clusters) are coloured from black to yellow to show how close 
each neuron's weight is to that of its neighbours. 
 
  
Figure 12: SOM layer with each neuron showing the number of inputs (patients) that it classifies. The 
relative number of patients for each neuron is shown via the size of a coloured patch. 
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Figure 13: SOM layer with each neuron showing the number of inputs (patients) that it classifies from 
each subtype (LumB, LumA, Normal Like, Basal Like and Her2).  
LumB:      LumA: 
       
 
 
Normal:     Basal: 
       
 
Her2: 
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When the SOM representation is broken down to show results for samples from a particular 
subtype – LumA, LumB, Normal, Basal, and Her2 – we can see (Figure 13) that there are 
discrete patterns observable, suggesting that the subtypes are, for the most part, separate 
entities. LumB mostly occupies the lower right quadrant; LumA covers most of the right-hand 
side of the map; Normal accounts for the upper central region; Basal on the left, mostly the 
upper-left corner; and Her2 represents mostly the lower left-hand-side of the map. However, 
there is some degree of overlap; for example, the bottom-right neuron has a total of nineteen 
patients, eleven of them coming from LumA, seven from LumB, and one from Her2. Also, 
the bottom-left neuron has a total of twenty-five patients; these are shared between Basal and 
Her2, with the latter having the majority. There are also some less pronounced overlaps. 
Because this method only partially confirms the existence of the five subtypes, with some 
overlap being apparent between them, we need to find a method of clearly and unambiguously 
identifying and distinguishing between the subtypes.  
 
Figure 14: Ward likelihood index for various numbers of clusters of SOM map neurons. 
 
54 
 
Figure 14 demonstrates that putting the data (trained neuron weights) obtained from the SOM 
method (on selecting the suitable set of criteria of SOM method (i.e. patch learning tools) to 
obtain reproducible result) through the Ward statistical analysis can help in identifying the 
most likely number of clusters. The figure shows that 7 clusters are present with high 
probability. This means that there are two other clusters that have not been identified by the 
original researchers using the same set of data. The figure also shows the possibility of the 
presence of two and with much less probability of ten clusters. 
 
To test the significance of these observations in relation to the original authors’ work, the 
clusters identified by the current analysis were analysed further to find the distribution of the 
patients between these clusters, and compare the calculated distributions with that of the 
original authors’. The analysis identified the clusters and assigned the appropriate patients in 
each cluster. The identified patients were matched with those identified by the original 
authors.   
 
Table  4.9 shows the distribution of the patients between two clusters as identified in the 
present study and further highlighted in Figure 15.  By matching the patient numbers with 
those numbers in the clusters that were identified by the original authors, we found that 
LumB, LumA and Normal Like subtypes belong to cluster1 in this work, while the Basal Like 
and Her2 belong to cluster2. These results are identical to those obtained from the 
Hierarchical-Ward analysis (Table  4.1). 
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 Table ‎4.9: Two clusters obtained from the SOM-Ward method including the number of patients in each 
cluster. 
Current Study 
 
Cluster 1 Cluster 2 Total 
No of Patients 161 88 249 
Subtypes LumB, LumA & Normal Basal & Her2  
 
The same calculation procedure was followed to identify the distribution of patients between 
the subtypes. Table  4.10 shows the number of patients and their sequence in each subtype 
according to the original authors’ data. When those patients numbers were matched with the 
number sequence identified by the current analysis (Appendix D) it was found that the 
sequence of the patients belonging to LumB, LumA and the Normal Like subtypes 
(representing cluster 1) matched (100%) the sequence reported in the original research.  
On the other hand, the sequence of the patients belonging to Basal Like and the Her2 subtypes 
(representing cluster 2) matched the sequence reported in the original research by 98% and 
83%, respectively. The remaining 2% and 17% of patient numbers were located in cluster 1. 
These results are identical to the findings from Hierarchical-Ward analysis (Table  4.2).  
 
Table ‎4.10: Comparison of the two clusters obtained from the current SOM-Ward with the original 
subtypes  
 
Original Author's data 
 
 
LumB LumA Normal Basal Her2 
 
No of patients 46 90 19 65 29 249 
Sequence order of 
patient number 
1 to 46 47 to 136 137 to 155 156 to 220 221 to 249 
 
SOM to the original % 100% 100% 100% 98% 83% 
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Figure 15: A dendrogram specifying the two clusters of patients (at cut off point 3000) according to their 
correlation strength 
 
 
Based on a cut off point 1050 in Figure 16, five clusters were identified for the purpose of 
comparison with the original study because the original research work reported the presence 
of 5 clusters only. These clusters were matched with the original 5 subtypes to examine the 
accuracy of the method used here.  
 
It was found that 67% of the patients of LumB were present in sub-cluster 1, 30% in sub-
cluster 2 and 2% in other sub-clusters of this work (Table  4.11, Table  4.12 and Appendix D). 
Similarly, 50% of the LumA was in sub-cluster 3, 43% in sub-cluster 2 and 7% in sub-cluster 
1 of the present work. Likewise, 95% of the Normal Like subtype was present in sub-cluster 3 
and 5% in sub-cluster 2 and none in the other subtypes. Sub-cluster 4 contained 86%, sub-
cluster 5 contained 12% and the other sub-clusters contained 2% of the Basal Like subtype, 
respectively. Finally, 79%, 10% and 10% of the Her2 subtype were in sub-cluster 5, sub-
cluster 3 and other sub-clusters, respectively.  
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This clearly indicates that the present results have similarities, to varying degrees, to those of 
the original researchers. However, the results also indicate that there is a clear overlap 
between the subtypes, especially between LumB, LumA and Normal Like subtypes. We 
noticed in Table  4.12 that patients from sub-cluster 1, sub-cluster 2 and sub-cluster 3 
(belonging to cluster 1 in Table  4.9) contain all LumB, LumA and Normal Like subtypes. 
Sub-cluster 4 and sub-cluster 5 represent majority of Basal Like and Her2, with sub-cluster 1 
and sub-cluster 3 sharing the rest. This confirms the earlier finding as explained in Table  4.9 
and Table  4.10 regarding the overlapping of patients between the sub-clusters. Such 
overlapping would in turn lower the confidence in using the genes as exclusive markers for 
the subtypes. 
 
Table ‎4.11: Current data of SOM five sub-clusters including the number of patients in each sub-cluster . 
SOM analysis data 
 
Sub-cluster  
1 
Sub-cluster  
2 
Sub-cluster  
3 
Sub-cluster  
4 
Sub-cluster  
5 
Total No of 
patients 
No of patients 40 54 67 57 31 249 
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Table ‎4.12: compression of the five clusters from SOM with the original dataset 5 subtypes (Hu et al. 
2006). 
Original authors’ data 
 
LumB LumA Normal Basal Her2 
Total No of 
Clusters 
No of Samples 46 90 19 65 29 249 
from 1 to 46 47 to 136 137 to 155 156 to 220 221 to 249 
 
S
O
M
 t
o
 t
h
e 
o
ri
g
in
al
 %
 
Clu1 Clu3 Clu3 Clu4 Clu5 
 
67% 50% 95% 86% 79% 
 
Clu2 Clu2 Clu2 Clu5 Clu3 
 
30% 43% 5% 12% 10% 
 
Clu3 Clu1 
 
Clu1 Clu1 
 
2% 7% 
 
2% 10% 
 
 
 
 
       Figure 16: A dendrogram specifying the five clusters of patients (at cut off point 1050) according to 
their correlation strength 
 
 
The overlapping in the five SOM-Ward sub-clusters raised the question of whether there are 
more unidentified sub-clusters. Our SOM-Ward analysis showed the possibility of the 
presence of seven sub-clusters (Figure 17). Examining these clusters (Table 4.14, Figure 17 
and Appendix D) showed that 67%, 30% and 2% of the LumB subtype were in sub-cluster 5, 
sub-cluster 6 and sub-cluster 3, respectively. Further, 43%, 24%, 26% and 7% of the LumA 
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subtype were in sub-cluster 6, sub-cluster 3, sub-cluster 4 and sub-cluster 5, respectively. 
Ninety five percent of the Normal Like subtype was in sub-cluster 3 and the remaining 5% 
was in sub-cluster 6. In addition, 55%, 31%, 12% and 2% of the Basal Like subtype were 
found sub-cluster 1, sub-cluster 2, sub-cluster 7 and sub-cluster 5 in that order. Finally, 79%, 
10%, 7% and 3% of the Her2 subtype were respectively in sub-cluster 7, sub-cluster 3, sub-
cluster 5 and sub-cluster 2. 
 
The seven sub-clusters analysis clearly indicates that there is a significant overlapping 
between the original five subtypes, plus the presence of two extra clusters that have not been 
identified before.  
 
Studying the overlap characteristics (between the original subtypes) showed that sub-cluster 3 
contained patients from all subtypes except Basal Like. On the other hand, sub-cluster 5 did 
not contain the Normal Like subtype. Furthermore, it was noticed that sub-cluster 3 and sub-
cluster 5 represented more of LumB, LumA and Normal Like subtypes than Basal Like and 
Her2 subtypes. 
 
It was found that although in the 2 cluster format (Table 4.9) the Basal Like and the Her2 
subtypes are represented by one cluster, in the 7 sub-cluster format, there is some overlap with 
LumB, LumA and Normal Like subtypes. However the overlapping involving sub-cluster 2 
and sub-cluster 7 was unique as they only shared Basal Like and the Her2 subtypes and did 
not contain LumB, LumA and Normal Like subtypes. By contrast, sub-cluster 6 was unique to 
the group containing LumB, LumA and the Normal Like subtypes. 
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The most significant observation was that sub-cluster 1 contained Basal Like subtype only, 
and sub-cluster 4 contained LumA subtype only. 
 Table ‎4.13: SOM seven clusters including the number of patients in each cluster. 
 
Sub-
cluster 1 
Sub- 
cluster 2 
Sub- 
cluster 3 
Sub- 
cluster 4 
Sub- 
cluster 5 
Sub- 
cluster 6 
Sub- 
cluster 7 
No of Patients 36 21 44 23 40 54 31 
 
Table ‎4.14: Comparison of the seven clusters from SOM with the original 5 subtypes (Hu et al. 2006). 
 
Author's data 
 
LumB LumA Normal Basal Her2 
No of Patients 46 90 19 65 29 
Sequence order of 
patient number 
1 to 46 47 to 136 137 to 155 156 to 220 221 to 249 
S
O
M
 a
s 
%
 o
f 
th
e 
o
ri
g
in
al
 
Clus 5 Clus 6 Clus 3 Clus 1 Clus 7 
67% 43% 95% 55% 79% 
Clus 6 Clus 3 Clus 6 Clus 2 Clus 3 
30% 24% 5% 31% 10% 
Clus 3 Clus 4 
 
Clus 7 Clus 5 
2% 26% 
 
12% 7% 
 
Clus 5 
 
Clus 5 Clus 2 
 
7% 
 
2% 3% 
 
 
 
 
 
 
 
 
Figure 17: A dendrogram specifying the seven clusters of patients (at cut off point 845) according to their 
correlation strength. 
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The turning now to the results of clusters from the perspective of subtypes, Table 4.15 
indicates that repeating the analysis of the same data used by the original authors with SOM-
Ward method produced identical (100%) results to those obtained by the Hierarchical-Ward 
method for the case of five sub-clusters.  This provides validity to our analysis methods.  
 
Introducing Ward analysis to our SOM analysis produced the likelihood of the presence of 
two clusters that divided into seven sub-clusters (Figure 14). Cluster 1 (Table  4.2) was 
divided into four sub-clusters (3, 4, 5 and 6, Table  4.16). Sub-clusters 5 and 6 in this analysis 
contained the same subtypes and percentages that were present in sub-clusters 1 and 2 of the 5 
sub-clusters analysis (Table 4.15). Sub-cluster 3 contained the same subtypes as those 
contained in sub-cluster 3 of the 5 sub-clusters analysis, but with different percentages (Table 
4.15). Unlike other sub-clusters, sub-cluster 4 contained LumA subtype only. This indicates 
that sub-cluster 4 could identify LumA patients with certainty.  
 
The analysis indicates that cluster 2 (Table  4.2) was divided into three sub-clusters (1, 2 and 7 
in Table  4.16). Sub-cluster 7 contained the same subtypes that were present in sub-clusters 5 
(the 5 sub-clusters analysis, Table 4.15) and with the exact percentages. Sub-cluster 1 in the 7 
sub-clusters analysis contained the Basal Like subtype only. This indicates that sub-cluster 1 
could identify Basal like subtype with certainty. Furthermore, sub-cluster 2 would identify 
Basal-like subtype with high likelihood as 95% of it is this subtype. 
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Table ‎4.15: The distribution comparison between the original five subtypes and the five sub-clusters 
obtained from the SOM-Ward method in the current study. 
SOM Current study - 5 sub-clusters 
 
Sub-cluster 1 Sub-cluster 2 Sub-cluster 3 Sub-cluster 4 Sub-cluster 5 
Total 
No of 
patients 
No of patients 40 54 67 57 31 249 
 
LumB (78%) LumA (72%) LumA (67%) Basal (98%) Her2 (74%) 
 
 
LumA (15%) LumB (26%) 
Normal 
(27%) 
Her2 (2%) Basal (26%) 
 
 
Her2 (5%) Normal (2%) Her2 (4%) 
   
 
Basal (3%) 
 
LumB (1%) 
   
 
Table ‎4.16: The distribution comparison between the original five subtypes and the seven sub-clusters 
obtained from the SOM-Ward method in the current study. 
SOM Current data -7 clusters 
 
Sub-
cluster 1 
Sub-
cluster 2 
Sub-
cluster 3 
Sub-
cluster 4 
Sub-
cluster 5 
Sub-
cluster 6 
Sub-
cluster 7 
Total 
No of 
patients 
No of 
patients 
36 21 44 23 40 54 31 249 
 
Basal 
(100%) 
Basal 
(95%) 
LumA 
(50%) 
LumA 
(100%) 
LumB 
(78%) 
LumA 
(72%) 
Her2 
(74%)  
  
Her2 (5%) 
Normal 
(41%)  
LumA 
(15%) 
LumB 
(26%) 
Basal 
(26%)  
   
Her2 (7%) 
 
Her2 (5%) 
Normal 
(2%)   
   
LumB 
(2%)  
Basal 
(3%)    
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Chapter Five 
 
5 DISCUSSION  
 
In this study new analysis based on two known clustering methods, namely, Hierarchical 
clustering and Self-Organizing Maps (SOM), has been applied. Unlike the work of the 
previous researchers (Sorlie et al. 2001 & 2003; Van't Veer et al. 2002; Sotiriou, et al. 2003; 
Hu et al. 2006; and Build et al. 2009) who used the Hierarchical clustering method only, the 
present study paired two different clustering methods with the Ward method. This is to 
investigate whether more details about the clusters found by Hu et al., (2006) can be obtained. 
Another aim is to ascertain the degree of overlap of subtypes, and to find the most significant 
reliable diagnostic markers for the known subtypes. 
 
Hu et at. (2006), stated that genes under study should be selected on the basis of their 
consistent expression when individual tumours are examined, but that vary in expression 
across different tumours. The pilot work analysis in this study aimed at finding the most 
significant genes in each of the five subtypes reported by Hu et al. (2006) study. The analysis 
identified genes that can be possibly considered as significant markers for the different 
subtypes, and some genes were exclusive to certain subtypes. These exclusive genes have not 
been identified as specific to each subtype previously. These genes are as follows: LumB 
(Hs.79136, Hs.1657, Hs.82961, Hs.396783, Hs.80420 and Hs.425311), LumA (Hs.79136, 
Hs.1657, Hs.82961, Hs.89603, Hs.169946 and Hs.390163), Normal Like (Hs.81665, 
Hs.334562, Hs.77204, Hs.80420, Hs.69771 and Hs.433871), Basal Like (Hs.82961, 
Hs.169946, Hs.437638, Hs.1657, Hs.26770 and Hs.2256) and Her2 (Hs.446352, Hs.86859, 
Hs.1657, Hs.9078, Hs.7913 and Hs.2986). 
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The results of the pilot work encouraged us to repeat the original work of Hu et al. (2006) but 
by introducing the Ward clustering to the Hierarchical clustering methods instead of the 
Hierarchical clustering on its own. The Hierarchical clustering produces a dendrogram that 
consists of many U-shaped lines connecting objects in a hierarchical tree of clusters, but it 
does not provide the optimum partitioning required by the user. Partitioning can be achieved 
by cutting the dendrogram at certain levels (cut off distance) (Samarasinghe 2007). Our 
approach was to use Ward and Hierarchical clustering methods simultaneously to merge 
clusters and to find the optimum cluster structure. As seen in the results, this analysis 
approach showed the presence of two main clusters that in turn are divided into six possible 
sub-clusters.  
These six sub-clusters contained significant percentages of the original patients’ distribution 
pattern which indicate that our analytical method is credible. The rest of the original patients’ 
were distributed among these six sub-clusters. This may explain the overlapping that was 
observed in the pilot analysis. Thus introducing the Ward method to the Hierarchical 
clustering method could help in obtaining more detailed description about the possible 
number of clusters and the distribution of the patients between clusters.  
 
Gene expression analysis using hierarchical clustering has categorized breast cancers into at 
least five main groups or subtypes (McCafferty, Healy et al. 2009). It is evident from the 
findings reported in the literature that integrating different analysis methods may produce 
more detailed outcomes. Huber et al. (2009) concluded that the effectiveness of target-specific 
therapies are still limited, but understanding of the heterogeneous biology of breast cancer can 
give clear direction for future research. 
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The new approach in this study takes into account the above observations and results are in 
agreement with those of Sorlie et al (2001) and Sotiriou, et al. (2003) who identified six 
subtypes, compared with the findings of Sorlie et al. (2003), Hu et al. (2006) and Build et al. 
(2009) who identified five subtypes only. 
 
The self-organizing map (SOM) helps in visualizing and interpreting large high-dimensional 
datasets. The introduction of the Ward method to the SOM in this study was to investigate 
whether the result obtained from the Hierarchical clustering method alone could be verified. 
The results showed high probability of two as well as seven clusters. The two clusters were 
identical to those found by the Hierarchical-Ward clustering method. The inspection of the 
seven sub-clusters showed that a unique overlap existed between the Basal Like and Her2 
subtypes, namely sub-clusters number 7 and 2 which shared these subtypes only (Table 4.14). 
It was also evident that sub-cluster number 1 represented only the Basal Like subtype.  
This study shows that sub-cluster number 6 was unique to LumB, LumA and Normal Like 
subtypes only, and did not represent the other subtypes. A significant outcome is that cluster 
number 4 represented LumA subtype only.  
 
Hu et al. (2006) selected genes that are consistently expressed when individual tumours are 
examined, but that vary in expression across different tumours. The results of the present 
study showed that certain genes that are significantly expressed in one subtype may also be 
significantly expressed in other subtypes too. This means that such genes cannot be 
considered as specific markers as indicated by Hu et al. (2006).  
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Hu et al. (2006) claimed that the basal subtype can be recognized as a distinct group and should 
be considered as a separate disease with respect to treatment and follow up. Our results may 
provide the explanation for why the basal subtype is more distinct. Our five sub-cluster results 
showed that when the Hierarchical-Ward analysis method was used, sub-cluster 4 uniquely 
represent the Basal Like subtype only. This finding was also confirmed by the results of SOM-
Ward analysis method. This may mean that the Basal Like subtype is more distinct than other 
subtypes. 
 
Sorlie et al. (2003) suggested that other subtypes are less clear, and require molecular definition 
refinement before they can be reliably defined and diagnosed. The results of the six sub-cluster 
analysis using the Hierarchical-Ward method in this study showed sub-cluster 2 was unique in 
LumA subtype only. Whilst the seven sub-clusters analysis using SOM-Ward method showed that 
sub-cluster 4 was unique in LumA subtype too. Introducing the Ward clustering method to both 
the Hierarchical and SOM may therefore, provide a means for more distinction between different 
subtypes.  
 
 
67 
 
Chapter Six 
 
6 CONCLUSIONS   
 
The ability to classify tumours by identifying recurrent gene expression patterns of hundreds 
or thousands of genes could enable identification of combinations of marker genes that may 
not be recognized by standard methods and help to get a deeper understanding of the function 
of gene interplay. Therefore, gene profiles that relate to prognosis may help define new 
therapeutic targets. The Hierarchical clustering method has been used as a standard tool to 
identify different clusters, but several researchers have indicated that the result obtained by 
this method may need refining to get a more clear result.  
 
This study introduced a new approach by combining the Ward method with the Hierarchical 
and SOM clustering methods. This approach produced more refined and detailed results about 
the properties of different clusters. For example, the same genes that are highly expressed in 
one subtype can be the most influential in one or more other subtypes.  Thus, the genes with 
more discriminating ability may not be the ones on the top of the list (ranked according to 
absolute expression ratio levels) but the ones found somewhere lower on the list.  This study 
found the few top most significant genes in each subtype (Table  4.1).   
 
This study showed that both the Hierarchical-Ward and SOM-Ward analysis produce two 
main clusters; one containing LumB, LumA and the Normal Like subtypes, and the other 
contain the Basal Like and the Her2 subtypes. These finding are in agreement with previous 
studies in this field of research. Our results showed that the two main clusters can be divided 
in to 6 sub-clusters (Hierarchical-Ward method) as has been reported in the literature, but the 
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present study with SOM-Ward method illustrated that 7 sub-clusters can also be obtained. 
Hierarchical-Ward and SOM-Ward results complemented each other very strongly that 
provided validity to the outcomes from the analyses conducted in this study.  Some of the 
identified sub-clusters in this study showed significant similarities to the findings of Hu et al. 
(2006) in terms of the distribution of samples (patients) among different sub-clusters. Both 
methods used in this study demonstrated that some sub-clusters contain one subtype only both 
found one cluster for LumA and SOM-Ward found distinct clusters for LumA and Basal like. 
Although these clusters containing a single subtype did not contain all the patients belonging 
to that subtype, it is worth investigating if these unique clusters define the core behaviour of 
these subtypes. 
 
The result of this study also showed that SOM-Ward method is a better tool for refining the 
results found from more basic cluster analysis methods.  
 
7 RECOMMENDATIONS 
 
We recommend the use of the simultaneous analysis method (Hierarchical-Ward and SOM-
Ward) to obtain more detailed outcomes from gene expression studies. We recommend that 
more experimental work be conducted with SOM for investigating any further refinements 
that can be made to separating the subtypes further.  For example, a larger SOM map size than 
the 25 neurons used in this study may provide more granularity to the separation of patients 
and could provide more clear separation boundaries for the subtypes owing to the ability of 
SOM to create complex nonlinear boundaries. 
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The Fuzzy C Means (FCM) or a related fuzzy clustering method is recommend as an 
alternative clustering approach that is generally considered as a better clustering tool for 
solving multiclass and ambiguous clustering problems than the Hierarchical and SOM 
clustering methods. Its goal is to determine the intrinsic grouping in a set of unlabeled data 
(Li, Lu et al. 2009). This method may provide extra information on the membership of 
patients in all subtypes thereby enabling the profiling of the core response of the subtypes and 
determining the likelihood of patients belonging to a particular subtype.     
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Appendix A 
 
Pilot results illustrating individual breast cancer subtypes. 
 
 
Figure 18: Bar graph illustrating the four most highly expressed genes in LumB vs. the expression of the 
same genes in the other subtypes based on median log ratio. 
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Figure 19: The median expression of the highly expressed gene in LumA (black colour) vs. its expression 
(green colour) in the rest of the examined subtypes. 
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Figure 20: Bar graph illustrating the four most highly expressed genes in LumA vs. the expression of the 
same genes in the other subtypes based on median log ratio. 
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Figure 21: The median expression of the highly expressed gene in Normal (black colour) vs. the same gene 
expression in the rest of the subtypes (green colour). 
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Figure 22: The median expression of the highly expressed gene in Her2 (black colour) vs. the same gene 
expression in the rest of the subtypes (green colour).  
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Figure 23: GGobi software based display of a scatterplot matrix for the 306 genes across the 249 patients 
for the subtypes highlighting only the most highly expressed genes visually and labelling them 
with different colours. 
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Figure 24: GGobi software based display of a time series (sequential) plot for the 306 genes across the 249 
patients in the five subtypes highlighting only the most highly expressed genes visually and 
labelling them with different colours. 
 
(Figure 23and Figure 24) Different format of the same data as in Figure 5 this led to the same 
conclusion with regard to identifying the subtypes. 
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Appendix B 
 
Hierarchical clustering results with several linkage methods. 
 
 
 
Figure 25: A dendrogram using hierarchical single linkage method representing the distribution of 
patients according to their correlation strength to clusters.  
 
 
Figure 26: A dendrogram using hierarchical average method representing the distribution of patients 
according to their correlation strength to clusters. 
 
83 
 
 
Figure 27: A dendrogram using hierarchical centroid method representing the distribution of patients 
according to their correlation strength to clusters. 
 
 
Figure 28: A dendrogram using hierarchical complete linkage method representing the distribution of 
patients according to their correlation strength to clusters. 
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Figure 29: A dendrogram using hierarchical median method representing the distribution of patients 
according to their correlation strength to clusters. 
 
 
 
Figure 30: A dendrogram using hierarchical Ward method representing the distribution of patients 
according to their correlation strength to clusters. 
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Figure 31: A dendrogram using hierarchical weighted method representing the distribution of patients 
according to their correlation strength to clusters. 
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Appendix C 
 
Patient labels in clusters from Hierarchical-Ward clustering. 
 
 
Hierarchical Two Clusters 
 
Cluster 1 Cluster 2 
1 157 
2 158 
3 159 
4 160 
5 161 
6 162 
7 163 
8 164 
9 165 
10 166 
11 167 
12 168 
13 169 
14 170 
15 171 
16 172 
17 173 
18 174 
19 175 
20 176 
21 177 
22 178 
23 179 
24 180 
25 181 
26 182 
27 183 
28 184 
29 185 
30 186 
31 187 
32 188 
33 189 
34 190 
35 191 
36 192 
37 193 
38 194 
39 195 
40 196 
41 197 
42 198 
43 199 
44 200 
45 201 
46 202 
47 203 
48 204 
49 205 
50 206 
51 207 
52 208 
53 209 
54 210 
55 211 
56 212 
57 213 
58 214 
59 215 
 
Hierarchical Five Clusters 
 
Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 
1 6 46 157 158 
2 18 47 159 213 
3 19 48 160 214 
4 20 49 161 215 
5 23 50 162 216 
7 28 51 163 217 
8 29 52 164 218 
9 30 55 165 219 
10 31 56 166 221 
11 32 65 167 222 
12 33 66 168 223 
14 35 68 170 225 
15 39 69 171 226 
16 54 88 172 227 
17 57 89 173 228 
21 58 90 174 229 
22 59 91 175 230 
24 60 92 176 231 
25 61 93 177 232 
26 62 96 178 233 
27 63 97 179 235 
36 64 98 180 236 
37 70 99 181 237 
38 71 100 182 238 
40 72 101 183 239 
41 76 108 184 240 
42 77 110 185 241 
43 78 111 186 243 
44 79 115 187 244 
45 80 116 188 245 
53 81 117 189 
 
73 82 118 190 
 
74 83 119 191 
 
75 84 120 192 
 
112 85 121 193 
 
128 86 122 194 
 
156 87 123 195 
 
242 94 124 196 
 
249 95 125 197 
 
 
102 127 198 
 
 
103 129 199 
 
 
104 131 200 
 
 
105 132 201 
 
 
106 133 202 
 
 
107 135 203 
 
 
109 137 204 
 
 
113 138 205 
 
 
114 139 206 
 
 
126 140 207 
 
 
130 141 208 
 
 
134 142 209 
 
 
136 143 210 
 
 
155 144 211 
 
  
145 212 
 
  
146 220 
 
  
147 234 
 
  
148 
  
  
149 
  
  
150 
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60 216 
61 217 
62 218 
63 219 
64 220 
65 221 
66 222 
67 223 
68 224 
69 225 
70 226 
71 227 
72 228 
73 229 
74 230 
75 231 
76 232 
77 233 
78 234 
79 235 
80 236 
81 237 
82 238 
83 239 
84 240 
85 241 
86 243 
87 244 
88 245 
89 
 
90 
 
91 
 
92 
 
93 
 
94 
 
95 
 
96 
 
97 
 
98 
 
99 
 
100 
 
101 
 
102 
 
103 
 
104 
 
105 
 
106 
 
107 
 
108 
 
109 
 
110 
 
111 
 
112 
 
113 
 
114 
 
115 
 
116 
 
117 
 
118 
 
119 
 
120 
 
121 
 
122 
 
123 
 
124 
 
125 
 
126 
 
127 
 
128 
 
129 
 
130 
 
  
151 
  
  
152 
  
  
153 
  
  
154 
  
  
246 
  
  
247 
  
  
248 
   
88 
 
131 
 
132 
 
133 
 
134 
 
135 
 
136 
 
137 
 
138 
 
139 
 
140 
 
141 
 
142 
 
143 
 
144 
 
145 
 
146 
 
147 
 
148 
 
149 
 
150 
 
151 
 
152 
 
153 
 
154 
 
155 
 
156 
 
242 
 
246 
 
247 
 
248 
 
249 
  
 
 
 
Hierarchical Six Clusters 
 
Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 Cluster 6 
46 52 1 6 157 158 
47 55 2 18 159 213 
48 56 3 19 160 214 
49 88 4 20 161 215 
50 89 5 23 162 216 
51 90 7 28 163 217 
65 91 8 29 164 218 
66 92 9 30 165 219 
67 93 10 31 166 221 
68 96 11 32 167 222 
69 97 12 33 168 223 
110 98 13 34 169 224 
111 99 14 35 170 225 
115 100 15 39 171 226 
116 101 16 54 172 227 
117 108 17 57 173 228 
118 121 21 58 174 229 
119 122 22 59 175 230 
120 123 24 60 176 231 
127 124 25 61 177 232 
129 125 26 62 178 233 
133 131 27 63 179 235 
135 132 36 64 180 236 
89 
 
137 
 
37 70 181 237 
138 
 
38 71 182 238 
139 
 
40 72 183 239 
140 
 
41 76 184 240 
141 
 
42 77 185 241 
142 
 
43 78 186 243 
143 
 
44 79 187 244 
144 
 
45 80 188 245 
145 
 
53 81 189 
 
146 
 
73 82 190 
 
147 
 
74 83 191 
 
148 
 
75 84 192 
 
149 
 
112 85 193 
 
150 
 
128 86 194 
 
151 
 
156 87 195 
 
152 
 
242 94 196 
 
153 
 
249 95 197 
 
154 
  
102 198 
 
246 
  
103 199 
 
247 
  
104 200 
 
248 
  
105 201 
 
   
106 202 
 
   
107 203 
 
   
109 204 
 
   
113 205 
 
   
114 206 
 
   
126 207 
 
   
130 208 
 
   
134 209 
 
   
136 210 
 
   
155 211 
 
    
212 
 
    
220 
 
    
234 
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Appendix D 
 
Patient labels in clusters from SOM-Ward clustering. 
 
 
SOM Two Clusters 
 
Cluster 1 Cluster 2 
1 157 
2 158 
3 159 
4 160 
5 161 
6 162 
7 163 
8 164 
9 165 
10 166 
11 167 
12 168 
13 169 
14 170 
15 171 
16 172 
17 173 
18 174 
19 175 
20 176 
21 177 
22 178 
23 179 
24 180 
25 181 
26 182 
27 183 
28 184 
29 185 
30 186 
31 187 
32 188 
33 189 
34 190 
35 191 
36 192 
37 193 
38 194 
39 195 
40 196 
41 197 
42 198 
43 199 
44 200 
45 201 
46 202 
47 203 
48 204 
49 205 
50 206 
51 207 
52 208 
53 209 
54 210 
55 211 
56 212 
57 213 
58 214 
59 215 
60 216 
 
SOM Five Clusters 
 
Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 
1 6 46 157 158 
2 18 47 159 213 
3 19 48 160 214 
4 20 49 161 215 
5 23 50 162 216 
7 28 51 163 217 
8 29 52 164 218 
9 30 55 165 219 
10 31 56 166 221 
11 32 65 167 222 
12 33 66 168 223 
14 35 68 170 225 
15 39 69 171 226 
16 54 88 172 227 
17 57 89 173 228 
21 58 90 174 229 
22 59 91 175 230 
24 60 92 176 231 
25 61 93 177 232 
26 62 96 178 233 
27 63 97 179 235 
36 64 98 180 236 
37 70 99 181 237 
38 71 100 182 238 
40 72 101 183 239 
41 76 108 184 240 
42 77 110 185 241 
43 78 111 186 243 
44 79 115 187 244 
45 80 116 188 245 
53 81 117 189 
 
73 82 118 190 
 
74 83 119 191 
 
75 84 120 192 
 
112 85 121 193 
 
128 86 122 194 
 
156 87 123 195 
 
242 94 124 196 
 
249 95 125 197 
 
 
102 127 198 
 
 
103 129 199 
 
 
104 131 200 
 
 
105 132 201 
 
 
106 133 202 
 
 
107 135 203 
 
 
109 137 204 
 
 
113 138 205 
 
 
114 139 206 
 
 
126 140 207 
 
 
130 141 208 
 
 
134 142 209 
 
 
136 143 210 
 
 
155 144 211 
 
  
145 212 
 
  
146 220 
 
  
147 234 
 
  
148 
  
  
149 
  
  
150 
  
  
151 
  
91 
 
61 217 
62 218 
63 219 
64 220 
65 221 
66 222 
67 223 
68 224 
69 225 
70 226 
71 227 
72 228 
73 229 
74 230 
75 231 
76 232 
77 233 
78 234 
79 235 
80 236 
81 237 
82 238 
83 239 
84 240 
85 241 
86 243 
87 244 
88 245 
89 
 
90 
 
91 
 
92 
 
93 
 
94 
 
95 
 
96 
 
97 
 
98 
 
99 
 
100 
 
101 
 
102 
 
103 
 
104 
 
105 
 
106 
 
107 
 
108 
 
109 
 
110 
 
111 
 
112 
 
113 
 
114 
 
115 
 
116 
 
117 
 
118 
 
119 
 
120 
 
121 
 
122 
 
123 
 
124 
 
125 
 
126 
 
127 
 
128 
 
129 
 
130 
 
131 
 
  
152 
  
  
153 
  
  
154 
  
  
246 
  
  
247 
  
  
248 
   
92 
 
132 
 
133 
 
134 
 
135 
 
136 
 
137 
 
138 
 
139 
 
140 
 
141 
 
142 
 
143 
 
144 
 
145 
 
146 
 
147 
 
148 
 
149 
 
150 
 
151 
 
152 
 
153 
 
154 
 
155 
 
156 
 
242 
 
246 
 
247 
 
248 
 
249 
  
 
 
 
SOM Seven Clusters 
 
Cluster 
1 
Cluster 
2 
Cluster 
3 
Cluster 
4 
Cluster 
5 
Cluster 
6 
Cluster 
7 
157 159 46 52 1 6 158 
167 160 47 55 2 18 213 
168 161 48 56 3 19 214 
169 162 49 88 4 20 215 
170 163 50 89 5 23 216 
172 164 51 90 7 28 217 
173 165 65 91 8 29 218 
181 166 66 92 9 30 219 
182 171 67 93 10 31 221 
183 174 68 96 11 32 222 
184 175 69 97 12 33 223 
185 176 110 98 13 34 224 
186 177 111 99 14 35 225 
187 178 115 100 15 39 226 
188 179 116 101 16 54 227 
189 180 117 108 17 57 228 
190 204 118 121 21 58 229 
93 
 
191 205 119 122 22 59 230 
192 211 120 123 24 60 231 
193 212 127 124 25 61 232 
194 234 129 125 26 62 233 
195 
 
133 131 27 63 235 
196 
 
135 132 36 64 236 
197 
 
137 
 
37 70 237 
198 
 
138 
 
38 71 238 
199 
 
139 
 
40 72 239 
200 
 
140 
 
41 76 240 
201 
 
141 
 
42 77 241 
202 
 
142 
 
43 78 243 
203 
 
143 
 
44 79 244 
206 
 
144 
 
45 80 245 
207 
 
145 
 
53 81 
 
208 
 
146 
 
73 82 
 
209 
 
147 
 
74 83 
 
210 
 
148 
 
75 84 
 
220 
 
149 
 
112 85 
 
  
150 
 
128 86 
 
  
151 
 
156 87 
 
  
152 
 
242 94 
 
  
153 
 
249 95 
 
  
154 
  
102 
 
  
246 
  
103 
 
  
247 
  
104 
 
  
248 
  
105 
 
     
106 
 
     
107 
 
     
109 
 
     
113 
 
     
114 
 
     
126 
 
     
130 
 
     
134 
 
     
136 
 
     
155 
  
 
 
